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ABSTRACT 
Natnaree Aimyong: Propensity Score Methods for Competing Risks 
(Under the direction of Jason P. Fine and M. Alan Brookhart) 
 
 Non-experimental studies have increasingly been used to examine the safety and 
effectiveness of medication. Challenges to this method include confounding, which may cause 
the estimator to be biased. Propensity score (PS), which is the conditional probability of 
receiving treatment given all confounders, may be used to control for confounding. Analysis of 
vulnerable populations may involve competing risks, which may occur before the event of 
interest. Statistical methods that account for competing risks are needed to obtain valid causal 
estimate. However, little knowledge attention has been given to this topic in the literature. 
 The objective of this research was to investigate the performance of estimators under 
implementation of various PS methods in competing risk survival analyses for estimating 
marginal and conditional treatment effects. The competing risk models were a cause-specific 
hazard model and subdistribution hazard model. 
According to simulation results, the weighted method produced efficient estimators for 
marginal treatment effects. However, it leads to an inflated variance when low incidence of event 
and strong confounder effects. A bootstrapping method can be used to estimate the variance 
under this scenario. For the conditional treatment effect, PS adjustment in the model performed 
the best for the null model. Depending on the sample size and the number of confounding 
variables, the subclassification and matching methods yield best performance under the 
alternative when treatment effect is non-null. 
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 Heterogeneity of treatment effect associated with statin therapy may be present in el- derly 
who experience myocardial infarction. Examining treatment effect across age groups and the 
revascularization procedure illustrated the heterogeneity of statin effects. Statins significantly reduce 
risks of heart failure among younger age groups. The combination of statins with revascularization 
procedures presents better treatment effects than occurs with statins alone. Application of propensity 
score methods to competing risks is illustrated in this study, with the analysis of treatment effects 
providing an improved understanding of the heterogeneity of the effects of statins therapy. 
The efficiency of implementing propensity score method to competing risks is illustrated in 
this study. Analyzing the treatment effects by subgroup and medical procedure contributes better 
results for estimating the heterogeneity treatment effect. 
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Chapter 1
Introduction
1.1 Motivating Examples
Cardiovascular disease (CVD) is the leading cause of mortality and is a major cause
of morbidity in the United States and worldwide (108). Increasing steadily with age, the
prevalence of CVD events is even higher in the population older than 65 years of age,
aﬀecting more than 70% of both men and women and 66% of CVD deaths occur in people
age above 75 years old (92). As the population is aging, more people are likely to have
cardiovascular complications. Increasing attention has been drawn to the management
of CVD in the elderly population.
Statins, a class of 3-hydroxy-3-methlglutaryl coenzyme A reductase inhibitors, are
used to lower low-density lipoprotein cholesterol (LDL-c) levels to prevent CVD events
(100). LDL-c has been recognized as an established risk factor for CVD events, and re-
mains the primary focus for evaluation of pharmacologic eﬀectiveness based on treatment
target goals. Clinical trials have demonstrated that statins are highly eﬀective at lower-
ing LDL-c and thus help to reduce the incidence of cardiovascular events(32, 90, 112).
Post-myocardial infarction (MI) patients with high normal or only mildly elevated lipid
levels also benefit from statin treatment (85, 23). However, older populations were not
well represented in most statin trials or age-specific results were not reported. As a re-
sult, little is known about the benefits of treatment with statins in the elderly, especially
among the elderly patients who just had a MI.
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Non-experimental studies are increasingly used to evaluate the safety and eﬀective-
ness of medications when used in usual clinical care (11). It is an appealing design for
investigation of statin treatment eﬀects among post MI patients. However, two major
challenges are present. The first challenge is presence of possible confounding systematic
diﬀerences in prognosis between patients treated with statins and those untreated. If
left uncontrolled, the observed diﬀerence in outcome risks cannot be interpreted as a
causal eﬀect solely due to statins. Another challenge is the presence of competing risks,
as the occurrence of some events may precede and thus preclude the occurrence of the
event of interest. In the elderly population after an acute MI, multiple comorbidities and
worsened health status put them at a higher risk of mortality. Death may thus preclude
the occurrence of the event of interest, (such as another MI) and make the evaluation
of the eﬀect of statins on MI diﬃcult. Sophisticated methods such as competing risks
survival analyses are needed in this setting (7, 64). Statistical methods that can account
for both competing risks and confounding are needed to obtain a valid causal estimate.
A competing risks survival analysis is a method to address the presence of multiple
events in a survival analysis of the time between the start of follow-up and either the
occurrence of the event(s) of interest or a censoring event (51). The outcomes of compet-
ing risk model are three mutually exclusive events including occurrence of the event of
interest, occurrence of a competing event, and a censoring event (lost to follow-up, end
of follow-up etc.). The regression models in competing risks may be used to estimate the
treatment eﬀects.
The classical approach for confounding control is based on multivariable regression
models. This approach may be heavily model dependent, with diﬀerent models po-
tentially giving very diﬀerent results. Moreover, the correct outcome model specification
can be challenging, especially in the settings of rare outcomes, many confounders, and/or
treatment heterogeneity (11, 14). Matching and stratification methods are popular tools
used to control confounding factors. However, these methods have diﬃculties when ap-
plied to a large number of confounders. Propensity score (PS) methods, which estimate
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treatment eﬀects without relying on modeling the outcome, are an approach being in-
creasingly used in non-experimental studies (96).
Competing risk survival analyses with PS methods to control for confounding can then
be used to investigate eﬀect of statin treatment on cardiovascular events among post MI
patients. However, this approach has not been extensively explored, and little is known
about the performance of this approach compared to the existing standard methods. It is
of great interest to investigate the performance of competing risk models using propensity
score methods to control confounding for estimating marginal and conditional treatment
eﬀects.
1.2 Causal Inference
Causal inference is the process of drawing a conclusion about whether a causal rela-
tionship does in fact exist (43). Let Yi(1) and Yi(0) be the potential outcomes that would
have been observed for individual i in the treatment group or the control (untreated)
group, respectively. Individual causal eﬀects can then be obtained by contrasting the
values of the two potential outcomes. However, only one of the potential outcomes is ob-
served for each individual, thus, in general, individual causal eﬀects cannot be obtained.
Since it is generally impossible to identify individual causal eﬀects, an aggregated
causal eﬀect, the average causal eﬀect in a population of individuals, becomes the focus of
interest. Let P [Yz = 1] be the counterfactual risk of outcome Yz, or the risk of developing
outcome Y in all subjects in the population receiving counterfactual treatment z. An
average causal treatment eﬀect is present when
P [Yz=1 = 1] ￿= P [Yz=0 = 1].
The assumptions of causal inference are the stable unit treatment value assumption
(SUTVA) and strong ignorability. SUTVA means the potential outcome of individual
i is independent of potential outcome of individual j, i ￿= j. The strong ignorability
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assumption is the independence of treatment assignment and outcomes conditional on
the covariates.
In randomized trials, only one potential outcome is observed for each individual.
However, the randomization process ensures that the balancing between the background
variables between treated and untreated groups. In other words, the randomization pro-
cess ensures the independent predictors of the outcome are equally distributed between
the treated and untreated groups. The treated and untreated groups are exchangeable,
and the exchangeability thus implies lack of confounding (65).
In non-experimental studies, treatment is not randomly assigned and the reason for
receiving treatment is likely to be associated with some predictors of the outcome. Thus,
exchangeability is not guaranteed. However, in weaker conditions, conditioning on many
pre-exposure covariates of the treated and untreated groups is often reasonable to allow
exchangeability. Let L be the confounding or background covariates. The conditional
exchangeability implies
P [Y = 1|L = 1, Z = z] = P [Yz = 1|L = l]
PS is the conceptual tool used to achieve accurate causal inference by balancing or
conditioning on the background variables of treated and untreated subjects (57).
1.3 Propensity score and non-experimental studies
A major challenge for non-experimental studies is confounding caused by systematic
diﬀerences in prognosis between patients exposed to intervention of interest and the
comparison group. Sources of confounding in non-experimental studies of medications
can arise from multiple areas. Physicians may tend to prescribe medications to patients
who are most likely to benefit from them, which can cause the intervention to appear to
cause events that they actually prevent (91). Patients initiating a preventive medication
may be more aware of their health status and more likely to engage in other healthy,
prevention-oriented behaviors leading to the bias known as healthy user bias (11). The
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validity of the treatment eﬀect estimated from non-experimental studies is a concern if
these biases are left uncontrolled.
Propensity score methods have emerged as a useful method to control for confounding
in the non-experimental setting. It is widely used in a variety of areas, including medical
(95), economic (42) and social research (67). The methods were formalized by Rosenbaum
and Rubin (80) and were shown to be able to control confounding. At the beginning,
the propensity score was developed to estimate the causal eﬀect of binary treatment
(48). A propensity score is the conditional probability of receiving treatment given all
confounders. Among patients with the same PS, treatment is unrelated to confounders.
Therefore, the two treatment groups have the same distribution of measured confounders.
The true propensity score of non-randomization studies is unknown. However, it can
be estimated from observed data. Statistical methods such as logistic regression and other
discriminant models can be used to estimate PS. Multivariable logistic regression is the
most widely used method for PS estimation. The estimation of the propensity score can
be implemented as a continuous variable via standard approaches including matching,
subclassification (stratification) by propensity score, propensity score adjustment to the
multivariate model, and weighting (96).
1.3.1 Matching
Matching on certain covariates to remove confounding by the matching variables
has been used extensively in cohort studies (96). Matching methods attempt to choose a
single or multiple patients from the untreated group with the same values of the matching
variables for each patient in the treated group. It can be easily implemented when
matching only needs to be done for a small number of covariates. A large number of
confounders in a non-experimental study makes matching on all confounders diﬃcult.
PS as a summary score reduces these multidimensional confounders to one dimension,
which helps overcome this limitation (19).
Rosenbuam and Rubin recommended three multivariate matching criteria (82). The
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first option is nearest available matching on the estimated PS. The treated and un-
treated patients are first randomly ordered, and the first treated patient is matched with
the first untreated patient who has the nearest PS. The second option is Mahalanobis
metric matching (84). The Mahalanobis distance is the distance between two dimen-
sional points scaled by the statistical variation in each component of the point. Treated
and untreated patients are first randomly ordered, and then each treated patient is pair-
matched with the first untreated patient who has the closest Mahalanobis distance. The
third alternative is nearest available Mahalanobis metric matching within calipers defined
by PS. The treated group is first randomly ordered. For each treated patient, a group of
untreated patients are chosen given that the diﬀerence of PS between the treated patient
and the untreated patient is less than the caliper (a constant value). From this group of
untreated patients, the patient who has the closest Mahalanobis distance to that of the
treated patient is selected as the match. The third matching method produces the best
balance for the covariate distributions between the treated and untreated groups and is
considered to outperform the first two.
The two popular algorithms for creating PS matched sets are greedy matching and
optimal matching . In greedy matching, a treated patient is first selected at random.
The untreated patient whose PS is closest to this patient is chosen as a match for this
patient. This process is repeated until all the untreated patients have been matched to all
the treated patients or when all the treated patients have been matched. In contrast to
the greedy matching, which finds the nearest untreated patient, optimal matching tries
to minimize the total within-pair distance diﬀerences (83).
The most common implementation of PS matching is pair matching (one-to-one
matching). With pair matching, only one untreated patient with a similar value of PS
is matched to one treated patient to form matching pairs. Alternatives to pair matching
include many-to-one (M:1) matching (66) and full matching (33, 37, 77). In many-to-one
matching, a fixed or variable number of untreated patients are matched to each treated
patients. The approach to match with a variable number of untreated patients was found
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to have improved bias reduction. Full matching results in matched sets consisting of ei-
ther one treated patient and multiple untreated patients or one untreated patient and at
least one treated patient (77). Full matching removes bias better than pair matching and
may achieve the closer match than M:1 matching (37). However, fullmatching method
result in a wide range of ratio of treated to untreated patients (94).
In analyses using Cox proportional hazard models, PS pair-matching has been shown
to have the smallest amount of bias when compared to other methods (26, 4). Martens
showed the analysis from real data showed larger treatment eﬀects from matching and
subclassification compared to conventional Cox proportional hazard model (62).
1.3.2 Subclassification
Another method used to implement PS to control confounding is subclassification or
stratification of PS into equal-sized strata, estimation of the treatment eﬀect within these
strata and then combining the stratum-specific eﬀect estimates using a weighted-average
approach. Both treated and untreated groups are grouped into equal-sized strata based
on their PSs. In general, quintiles of PS are used to create the strata. Previous reports
have shown that subclassification into five strata can remove approximately 90% of initial
bias (81) despite the fact that it can also increase the variance of the estimator (104).
1.3.3 Propensity score covariate adjustment
Adding the PS to a multivariable outcome model is the least appealing method of PS
implementation, since the validity of this approach depends upon a correct specification
of both PS and outcome models. If the PS is included as a linear term in the outcome
model, an assumption is made that there is a linear relationship between the PS and the
outcome, which is likely to be violated in real world applications.
In situations where outcome models are linear models, this regression modeling method
is the same as analysis of covariance (ANCOVA). A great amount of bias can be intro-
duced when the covariances of the treated and untreated groups are unequal and the
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variances of the treated and untreated groups diﬀer (19). When this method is applied
to studies using survival analysis to estimate eﬀects, the fixed parameters of the PS vari-
able suggest that the probability of receiving treatment given all measured covariates
has a constant eﬀect on the hazard ratio. Results from our simulation study showed
that the eﬃciency of propensity score adjustment depended on the overlap area and the
specification of variables included into propensity score model (35).
1.3.4 Weighting
Standardization with weights generated from the PS can also be used to control
confounding. Unlike matching, this approach does not result in reduction of the original
sample size. Individuals within the original sample are weighted based on their PS to
create a pesudo-population where the covariates are well balanced in the two treatment
groups, and no association exists between the confounders and treatment. The weighting
method plays an importance role in the estimation of marginal treatment eﬀects. There
are two types of weighting commonly used: inverse probability of treatment weighted
(IPTW), standardized mortality ratio weighted (SMRW).
IPTW is defined as the inverse of the estimated PS for treated patients and the inverse
of one minus the estimated PS for untreated patients (76). These weights create a pseudo-
pupulation where the weighted treated group and untreated group are representative
of the patient characteristics of the entire population, resulting in an estimate that is
generalizable to the entire population from which the observed study sample was drawn.
The IPTW method has been shown to have good performance for estimating marginal
treatment eﬀects in Monte Carlo simulations (4). However, IPTW can be unstable in
some situations so a stabilized weighting method may be preferred. The stabilized weight
(STW) is calculated by multiplying the IPTW by the probability of being treated for the
treated patients and the probability of not being treated for the untreated group. STW
helps reduce the eﬀects of extreme weights and produces a narrower confidence interval
for the estimator compared to IPTW (17).
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SMRW is set to one one for treated patients and defined as the ratio of the estimated
PS to one minus the estimated PS for the untreated (86). The untreated patients are thus
weighted to be representative of the treated population. The resulting eﬀect estimate
is generalizable to the treated population from which the observed treated sample was
drawn. Unlike PS matching, which also often estimates average treatment eﬀect in the
treated, no treated patients are excluded from the analysis.
In all weighting analyses, statistical methods are needed to account for the relation
between the replicated individuals created by the process of weighting. A robust sandwich
variance estimate is required to calculate the variance. This approach results in confidence
intervals that are conservative and wider than the nominal coverage.
Many studies have applied weighted methods to survival analysis. Cole and Her-
nan presented an approach to produce adjusted survival curves with inverse probability
weights which oﬀers direct interpretation of the data (16). Hernan et al (40) applied
IPTW to study zidovedine (AZT) treatment eﬀects on mortality and compared it to an
unweighted analysis. The weighted analysis showed that AZT reduced risks of mortality
but the unweighted analysis with a basic baseline adjustment model produced an adverse
eﬀect of AZT on mortality (which was contrary to reality).
Simulation studies showed survival analysis via Cox model with application of the
IPTW method produced the smallest amount of bias for the estimator of interest (4, 26).
1.3.5 Variables selection for propensity score model
The identification of variables to be included in the PS model is an important process.
Good subject-matter knowledge must be used to guide this process. Studies have shown
that optimal PS models should include all variables that are related to the outcome of
interest, regardless of whether they are associated with the treatment. Including variables
that are related to treatment but which are either not related or only weakly related to
outcome increase the variability of eﬀect estimates and, in the presence of unmeasured
confounding, increase bias (10). This idea of variable selection for the PS also exists for
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the estimator of the average treatment eﬀect for the treated group when applying the
matching method and using a multinomial model for the outcome estimation (18, 110).
1.3.6 Assessment of the balance of the covariates
Once the PS model is fit, it is recommended to explicitly evaluate the performance of
the estimated PS model by assessing the balance of covariates after PS implementation
either through matching or weighting . Approaches to assess the covariate balance under
PS methods have been developed (3).
Evaluation of the lack of fit of the PS model is performed using the logistic regression
goodness-of-fit statistics and the c-statistic. the goodness of fit statistic summarizes the
deviation between the observed and predicted outcomes. The c-statistics value indicates
the capacity of a model to discriminate between treated subjects and untreated subjects
(46). However, both methods fail to detect the balancing of background variables between
treated and untreated groups (106).
The standardized mean diﬀerence can be applied to identify the importance of dif-
ference between the treated and untreated groups and to evaluate the covariate balance
in PS matching and weighting methods. Values of 0.2, 0.5 and 0.8 represent a small,
a moderate and a large diﬀerence, respectively; the sample size does not influence the
standardized diﬀerence (105). For subclassification method, the covariate balance can
be evaluated with a two-way analysis of variance (ANOVA). The treatment group and
subclassification group are the factors of the ANOVA model for testing the balance of co-
variates in the treated and untreated groups (81). The weighted conditional standardized
diﬀerence and quintile regression are the methods used to determine the similarity of the
baseline covariates in the treated and untreated groups (2). Recently, Imai and Ratkovic
(47) introduced a covariate balancing PS estimation method which optimizes the covari-
ate balance while estimating PS (38). This method can improve the performance of PS
weighting and matching methods.
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1.4 Marginal and conditional models
A marginal treatment eﬀect is the average treatment eﬀect for the population, while a
conditional treatment eﬀect is the average treatment eﬀect for the individual (3). In the
absence of confounding, the diﬀerence in means and risk diﬀerence are collapsible, and the
conditional and marginal eﬀects are the same. In randomized studies, the covariates are
balanced between the two treatment groups, therefore the crude diﬀerence in means and
the adjusted diﬀerence in means will be equal. In non-experimental studies, the marginal
and conditional estimates will coincide if there was no unmeasured confounding, the
outcome was continuous, and the true outcome model was known (31). However, when
the outcome is either binary or time-to-event, and the odds ratio or the hazard ratio
is used as the eﬀect measure, then the marginal and conditional eﬀect will not coincide
even in the absence of confounders (34, 25).
For PS methods, the estimators from the conventional model (adjusting for con-
founders in the outcome regression model), covariate adjustment (adding the PS to a
multivariable outcome model) and matching method are estimating the conditional treat-
ment eﬀect. The PS based weighting methods yield estimates of the marginal treatment
eﬀect for the population.
1.5 Competing risks model
A survival analysis explores the time period from a certain point until the occurrence
of the event of interest. A competing risks survival analysis is the special case of survival
analysis where multiple events may occur and the occurrence of one event may preclude
the occurrence of the other. Competing risk events threaten the validity of studies, even
in randomized control trials. Individuals who are at higher risk of competing risk events
may be less likely to experience the absolute benefit of treatment (64). Care is needed
in statistical analysis to ensure that treatment eﬀects are appropriately quantified.
Approaches have been developed to conduct competing risk survival analysis. The
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likelihood of the occurrence of a particular competing risk can be summarized using the
distribution of the observed data or using models representing the underlying mechanisms
that generated the observed data (54). When modeling the observed data, so-called crude
functions are utilized. The cause specific hazard and cumulative incidence functions
described below are the most widely used quantities. A popular mechanistic model
is the latent failure time model discussed below. The net function is the probability
of the occurrence of the event of interest corresponding to the latent failure time in
the hypothetical situation where the particular risk of event is the only risk present.
Additional properties of the crude and net approaches are now discussed.
1.5.1 Notation
For this discussion, the following notations are used. Let Y and C be failure and
censoring times, and ε ∈ {1, 2, ..J} be the failure event. For each individual i, i=1,...,n,
the observed failure time was Ti, T= (Y ∧C), and the observed event be εi, ∆ε = I(Y ≤
C) when I(·) is indicator function. Let Z be one for treated group and zero for untreated
group.
1.5.2 Latent failure times
There are J mutually exclusive types of failure events, and the corresponding time
until each failure type is ￿Tij. The observed time is minj(￿Tij), with each ￿Tij defined as
if the other causes were not present, and with the observed cause of failure ε being the
index of the observed latent failure time. The hazard function for latent failure times is
a net hazard function defined as:
￿λij = lim
∆t→0
1
∆t
P (t ≤ ￿Tij < t+∆t, ε = j|￿Tij ≥ t), j = 1, ..., J.
The net function can be estimated when the latent failure times are independent.
This assumption of independence cannot be verified, so this approach is not realistic for
applications in data analyses.
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1.5.3 Cause-specific hazard function
To model competing risk using a cause-specific hazard function, the type-specific or
cause-specific hazard function is defined as:
hj(t) = lim
∆t→0
1
∆t
P (t < T < t+∆t, ε = j|T ≥ t), j=1,...m.
The cause-specific hazard function is the instantaneous rate for a failure of type j at
time t, in the presence of all other failure types (54). With this cause-specific hazard
function approach, an event k (k ￿=j) is censored at time T if events other than type j are
observed. The cumulative incidence function, P (T ≤ t, ε = j),which is the probability of
occurrence of event j at time t is defined as:
Fj(t) =
￿ t
0
hj(s)S(s)d s , where S is the survival function for T.
Defining Si(t) to be the survival function based on hi(t) where S(t) =
￿
i Sj(t), one
may show that the naive Kaplan-Meier estimator for Si(t) is a biased estimator for Fi(t),
generally underestimating this quantity (73).
From the definition of the cause-specific hazard function, the parameters of the cause-
specific hazard model can be estimated using a Cox proportional hazard model. The
treatment eﬀects of event j can be obtained by maximizing the factor of the partial
likelihood function involving event j when other event(s) are treated as censoring events.
The semiparametric model of cause-specific hazard function is defined as:
hj(t) = h0j(t)exp{β￿jZ}
1.5.4 Subdistribution hazard function
The subdistribution hazard function is the other type of competing hazard function
which is derived directly from cumulative incidence function (30),
λj = {dFj(t)dt}/{1− Fj(t)}.
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The subdistribution hazard function is probabilistically defined as
λj(t) = lim
∆t→0
1
∆t
P (t < T < t+ δt, ε = j|T ≥ t ∪ (T ≤ T ∩ ε ￿= j).
For the subdistribution function, the cumulative probability of occurrence of cause J
remains less than one, the subdistribution satisfies the definition of an improper proba-
bility distribution. This occurs because an individual who had an event k no longer is at
risk of failure from causes j ￿= k.
Similarly to the cause specific hazard, a proportional hazards model may be specified
for the subdistribution hazard function to describe the treatment eﬀect on the risk of
a particular cause of interest. The parameters of this model can be estimated using
methods for the Fine-Gray model (21). The semiparametric model for subdistribution
hazard function is:
λj(t) = λ0j(t)exp{β￿jZ}
1.6 The application using Real Data
For this example, we identified a cohort of Medicare beneficiaries who just had a
hospitalization stay for acute MI (AMI) in 2008. The condition AMI was identified from
Medicare inpatient claims files using relevant International Classification of Diseases,
Ninth Revision, Clinical Medication (ICD-9-CM) codes (410.01, 410.11, 410.21, 410.31,
410.41, 410.51, 410.61, 410.71, 410.81, 410.91). Personal identifiers were removed from
all analytical data files.
Eligible patients included in the cohort were at least 66 years old at the admission
date, living in the United States and had been continuously enrolled in Medicare Part
A at least one year. The exclusion criteria included the absence of specific ICD codes
(410.x1) as the first or second discharged diagnosis, patients who died during hospital
admission, patients who did not survive 30 days after discharge, AMI diagnosed only
from skilled nurse facility (SNF) claims, patients who only had AMI admission prior
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to 1/1/2008 and were discharged on or after 1/1/2008. Other exclusions were patients
who had discharge code to hospice (40, 41, 42, 50, 51), transfered to other hospitals
for inpatient care, patients who were discharged or transfered to SNF or long-term care
facilities for inpatient care, or who did not have a prescription claim within 30 days after
the index AMI discharge.
The exposure of interest was statin use after discharge. Patients initiating statin
therapy were considered statin users while patients without statin prescriptions were
considered nonusers. The follow up of these patients started at 31 days following the
date of discharge and ended at the occurrence of the outcome or at the end of the study.
The outcome of interest was the occurrence of MI or heart failure (HF) or stroke or all-
cause mortality. The eﬀect of interest in this example was the marginal and conditional
treatment eﬀect of statins on the cardiovascular outcomes or mortality in the presence
of competing risks.
Potential confounding covariates were created, including demographic characteristics
and clinical conditions based on claims occurring in the 12-month baseline period prior to
admission were created. These covariates were identified a priori based on the literature,
substantive knowledge, and the availability of covariates within the data. The variables
included both demographic and medical record at baseline, during admission and follow
up period. A list of these covariates appears in Table 1.1.
1.7 Objective and outline
The objective of this research study was to investigate the performance of estimators
when using various PS implementation methods in competing risk survival analyses for
estimating of marginal and condition treatment eﬀect. The PSs were estimated using
logistic regression. The implementation methods examined included subclassification,
matching, PS adjusted into the model and weighting. The competing risks models used
were the cause-specific hazard model and the subdistribution hazard model.
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Chapter 2 describes the performance of PS methods incorporated in the competing
risk survival analytic approach for estimation of marginal treatment eﬀects. Chapter 3
presents the performance of PS methods incorporated in competing risk survival analyses
for conditional treatment eﬀects. The results presented in both chapters were from sim-
ulation studies as well as analyses of claims data evaluating the eﬀect of statin treatment
on the risk of cardiovascular end points and mortality. Chapter 4 presents an application
of the proposed methods in an evaluation of the heterogeneous treatment eﬀect of statins
across diﬀerent age groups and revascularization procedure groups.
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Table 1.1: Variables included into propensity score model
General character gender, age, race, income, medicare doughnut
Charlson Comorbidity AMI, Cerebrovascular Disease,
index Congentive HF, Periphral vascular disease,
Renal disease, Chronic Obstructive Pulmonary disease,
Diabetes,Peptic Ulcer disease, Cancer, Dementia,
Connective Tissue disease, Rheumatic disease,
Mild liver disease, Moderate to severe liver disease,
Paralysis, Metastatic Carcinoma, AIDS/HIV,
Diabetes with and without complication
Baseline disease CABG, STENT, PTCA, unstable angina
Ischemic heart disease, Hyperkalemia
Atrial fibrillation, Hypertension, Hyperlipidemia,
End-stage renal disease, Osteroporosis, Asthma,
Hypotension,Rhabdomyolysis, Sinus bradycardia
heart block, Angioedema&hyperkalemia, CCI total score
Baseline medication statins, STENT/PTCA, Beta blocker, ACEI/ARB
hospital admission in baseline, Number of admission
Number of days stay in hospital
Admission procedure Subendocardial infarction,Congestive HF
/diagnosis Cardiogenic shock, Acute renal failure, Hypotension,
Cardiac dysrhythmias, cardiac catheterization, CABG,
PTCA, Angiocardiography, Platelet inhibitors
Thrombolytics and platelet inhibitors
Acute respiratory failure in AMI admission
Septic shock in AMI admission, Days stay in ICU
Days stay in coronary care unit, Total days in hospital
Medication record Physician visit, Cardiologist visit,
during Follow-up Revascularization procedure,
Number of admission to short-term acute care hospital,
Number of days to short term acute care hospital,
Co-medication angiotensin-converting-enzyme inhibitor (ACEI)/
angiotensin receptor blocker (ARB), Beta blockers
Current comorbidity Valvular disease or rheumatic heart disease
and assistance Hypothyroidism, Other neurological disorders
Obesity, Coagulation deficiency, Substance abuse
Weight loss, Fluid/electrolyte disorder
Blood loss, deficiency anemia
Pulmonary Circ. Disorders, Parkinson’s disease
Osteoarthritis, Gastrointestinal bleed, Use of rehabilitation
Use of screening, use of wheelchair
Weakness, Vertigo, Fall/diﬃculty walking
Bladder dysfunction, Decubitus, Use of Oxygen
Use of hospital bed, Use of ambulance, Nail care
Use of other assistive devices
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Chapter 2
Marginal Treatment Eﬀects of Completing Risks Model
2.1 Introduction
A marginal treatment eﬀect is the average treatment eﬀect at the population level, de-
scribing the diﬀerence in outcomes between two comparable populations where everyone
in one population receives the treatment, while in the second population everyone receives
an alternative treatment or is untreated (75). It can be estimated in both experimental
and non-experimental settings. In the experimental setting, randomization balances the
characteristics of the treatment and control groups. With the assumption that all pa-
tients could receive either of the treatments under comparison and independence of the
treatment eﬀects among patients, the balancing of covariates between treatment groups
are expected, thus the crude analysis without any adjustment results in an unbiased esti-
mate of the marginal treatment eﬀect. Non-experimental studies based on administrative
claims or clinical databases are increasingly used for post-marketing safety and eﬀective-
ness evaluation of treatments (39). These studies allow for estimation of treatment eﬀects
in settings where randomized trials are impractical or unethical. The treatment alloca-
tion in non-experimental studies is often influenced by subject characteristics, however,
resulting in systematic diﬀerences between treatment groups possibly resulting in con-
founding or other bias. Thus, an unbiased estimate of the average treatment eﬀect cannot
be directly obtained by comparing outcomes between the two treatment groups.
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PS methods have emerged as a useful approach, formalized by Rosenbaum and Ru-
bin (80), to balance measured confounding between treatment groups and thus reduce or
minimize the eﬀect of confounding in the non-experimental setting when estimating treat-
ment eﬀects. The propensity score is the conditional probability of receiving treatment
given measured baseline covariates. Among patients with the same propensity score,
the treatment assignment is unrelated to measured covariates included in the propensity
score model. The two treatment groups then have the same distribution of measured
confounders, which enhances comparability between the groups. The propensity score,
a continuous variable, can be implemented in various ways, including: matching, sub-
classification (stratification), inclusion in multivariate modeling, and inverse-probability
weighting (80, 76). Of these, the matching and weighting methods play an important
role in estimating the marginal treatment eﬀect in the overall population. Under four as-
sumptions of (1) no unmeasured confounders, (2) positivity, (3) no misspecification, and
(4) consistency, weighting creates a pseudo-population in which exposure is independent
of confounding (17). Under assumption of no unmeasured confounders, the exposure and
outcome are independent within each level of a confounder variable, then the comparabil-
ity of treated and untreated groups exists (65). The positivity assumption specifies that
there are both treated and untreated subjects at every level of all confounder variables.
The third assumption (no misspecification) is that all models, including both the PS
models and the outcome model, are correctly specified (17). The consistency assumption
is formally defined such that the potential outcome of individual for a specific exposure
is the outcome that would be observed if he/she had received that specific exposure (15).
A competing risks survival analysis is the special case of survival analysis where
multiple events may occur and the occurrence of one event (e.g., death) may preclude the
occurrence of the event of interest. Competing events can threaten the validity of studies
interested in marginal eﬀects, even in randomized control trials (64). Competing risk
models can be summarized using the distribution of the observed data or using underlying
mechanistic models which generate the observed data. A popular mechanistic model
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is the latent failure time model, but it cannot be used without strong and unverifiable
assumptions making it unattractive for practical usage (72). When modeling the observed
data, so-called crude functions are utilized. The cause-specific hazard and cumulative
incidence functions, which are based on the observed data, are the most widely used. For
non-experimental studies of a time-to-event outcome with competing events, statistical
methods that account for both competing risks and the eﬀect of confounding are needed
to obtain a valid causal estimate of the marginal treatment eﬀect.
IPTW, generated from the propensity score, can be used to control for confounding.
The IPTW is defined as the inverse of the estimated likelihood of receiving the treatment
actually received, which is the propensity score for the treated patients and one minus the
propensity score for the untreated patients (76). The IPTW method creates a pseudo-
population representative of the patient characteristics of the source population, thus
producing an eﬀect estimate generalizable to the population from which the sample was
drawn. Assuming that the PS model was correctly specified, the measured covariates of
the pseudo-population are balanced across the two treatment groups, and no association
exists between measured confounders and treatment.
The IPTW method has been shown to have good performance in the estimation of
marginal treatment eﬀects in Cox proportional hazards models (98, 4, 26). However,
IPTW can be unstable sometimes and a stabilized weighting method can be used to
remedy the instability. The stabilized weight (STW) is calculated by multiplying the
IPTW with the marginal probability of the treatment actually received (being treated
for the treated group and one minus the probability of being treated for the untreated
group) (76). STWmethods reduce the influence of extreme weights and produce narrower
confidence intervals for the estimator compared with the non-stabilized IPTW (17). In
all weighting analyses, appropriate statistical methods are needed to account for the
correlation between the replicated individuals created in the weighting process. A robust
sandwich variance estimate is required to calculate the variance of the estimator. This
approach results in confidence intervals that are conservative and wider leading to higher
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than nominal coverage (59).
The objective of this study was to investigate the performance of the IPTW and the
STW in estimating the marginal treatment eﬀect using competing risks survival analysis
model. Both simulation and application in a substantive data analysis were performed.
2.2 Methods
2.2.1 Monte Carlo simulation
A series of Monte Carlo simulations were conducted in order to examine the per-
formance of inverse probability treatment weighting methods with two competing risk
models: the subdistribution hazard model and the cause-specific hazard model.
Let Z be the binary exposure and X be a vector of 10 confounding variables. For each
simulated dataset, the 10 covariates , Xl, l= (1,...,10) were generated from a Bernoulli
distribution with parameter 0.5. The probability that the exposure Z was equal to one,
which is the true propensity score, was estimated as a function of the covariates (α) using
a logistic model. The exposure indicator Z was drawn from a Bernoulli distribution with
probability set by
Pr(Z = 1|Xl) = α0 + ΣlαlXl
In order to evaluate the performance of the weighting methods in a range of settings,
four levels of confounding eﬀect and three level of proportion of interesting event were
considered. We generated the confounding eﬀects by iteratively varying αl untill the
desired Komogorov-Smirnov (KS) distance of 0.10, 0.25, 0.40 and 0.55 (Figure 1) were
reached. The larger KS distances represent the larger diﬀerence of covariates between
treated and untreated groups found in a non-randomized study, KS distances closer to
zero represent the diﬀerences found in a randomized study. The percentage of treated
group in the simulation setting was roughly 40%. The observed events of this study were
ε ∈{1,2}, ε=1 indicated events of interest and ε=2 indicated competing event. Three
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proportions of event of interest (ε =1) were generated, proportion (p) set in turn to 0.4,
0.6 and 0.8. The right censored times (Ci) were generated from a uniform distribution on
[0, 6] to have 20% censoring. All failure time variables were generated using a competing
risk model where treatment Z and covariates X were predictor variables. For individual
i, where the eﬀect of treatment, βj,, for failure ε=1 (with either the cause-specific hazard
or subdistribution hazard) was fixed at -0.5 and for failure ε=2 was fixed at -0.06, which
is the conditional treatment eﬀects.
The next two sections describe how the failure times were generated under the two
diﬀerent hazard functions under presence of competing risks. After which the detail of
estimating true treatment eﬀect for marginal model and PS estimated is described.
2.2.2 Simulation for subdistribution hazard function
The simulation method followed procedures described by Fine and Gray (21). The
failure time for ε=1, was generated from
Pr(Ti ≤ t, ε = 1|Z,X) = 1− [1− p{1− exp(−t)}]exp(Zβ1+Xlγl).
which is unit exponential with mass 1-p at infinity, Z, X =0 and p∈ {0.4, 0.6, 0.8}. The
subdistribution for ε = 2 was generated from Pr(ε = 2|Z) = 1 − Pr(ε = 1|Z) and
the time until failure event conditionally on ε = 2 was generated from an exponential
distribution with rate exp{β2Z + γl2Xl}.
2.2.3 Simulation for cause-specific hazard function
Let h1(t|Z,X) = θ1exp{β1Z + γl1Xl} and h2(t|Z,X) = θ2exp{β2Z + γl2Xl} be the
cause-specific hazard function, which is dependent on Z andXl, of event ε = 1 and event ε
= 2, respectively. The overall hazard rate was h(t|Z,X) = h1(t|Z,X) + h2(t|Z,X). The
failure time for each subject was generated from exponential distribution with hazard
rate h(t|Z,X). The event types, ε were generated from a Bernoulli experiment,
P (ε = 1|T < t) = h1(t|Z,X)h(t|Z,X)
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where the parameter values were chosen such that P (ε = 1|T < t) were 0.4, 0.6 and
0.8 for all t (9, 8).
2.2.4 True marginal treatment eﬀect
As discussed earlier, the true marginal treatment eﬀect can be estimated from a ran-
domized trial. We simulated a dataset with the same parameters and settings described
above to estimate the true marginal treatment eﬀect. This approach is necessary because
performing simulations using the models in 2.2.2 and 2.2.3 does not result in a marginal
proportional hazards model, that is, the marginal treatment eﬀect is not correctly spec-
ified via the proportional hazard models. If one employs the misspecified proportional
hazard model in a data analysis, the resulting estimator estimates a parameter defined
in large samples as the limiting value to which that estimator converges. This problem
generally occurs in survival settings, when confounders are included in the true survival
model and marginalizing over the confounders does not generally result in a proportional
hazard model. The notion of convergence just described is standard with misspecified
models, where parameter estimators do not converge to true values of parameters in the
underlying models.
To determine the limiting value of the parameter estimator, a dataset with a size
of 100,000 was generated. The same distributions for the confounders were used. The
treatment variable Z was generated from a Bernoulli distribution with a parameter of
0.5, which imitates the randomization process. The true marginal treatment eﬀect, mea-
sured as the diﬀerence in proportion of event of interest, was determined for both the
subdistribution hazard model and the cause-specific hazard model, based on fitting these
models using standard approaches. For the subdistribution hazard model, the approach
of Fine and Gray was used without propensity scores, while for the cause-specific hazard,
a standard partial likelihood analysis was utilized. Assuming consistency of the param-
eter estimator under the misspecified model, the estimator based on large sample size of
100,000 should be extremely close to the actual value being estimated.
23
2.2.5 Propensity-based estimation of the treatment eﬀect in simulations
For the simulated dataset, four diﬀerent types of marginal models were fitted with the
two diﬀerent competing risk analysis approaches: a crude model, a crude model based on
region of common support (13), weighted regression using IPTW and weighted regression
using STW. A conventional multivariable regression model, which is a conditional model,
was also fitted to investigate the performance of estimating marginal treatment eﬀects.
For the two competing risk approaches, treatment eﬀects from the cause-specific hazard
function were estimated using a Cox proportional hazard model, while treatment eﬀects
from the subdistribution hazard function were obtained from the Fine-Gray model. The
analyses were performed in R 3.0.1 (102) using the package survival for Cox models (103)
and the package cmprsk for the Fine-Gray model (29).
For the weighted analyses, weights were calculated from the estimated PS. We esti-
mated the PS, pˆ for individual i, using a multivariable logistic regression model:
logit(pˆ) = αˆ0 + ΣlαˆlXl
Weights for IPTW and STW were calculated using the following formulas:
IPTW =
Zi
pˆi
+
1− Zi
1− pˆi
STW = Z
Z¯
pˆi
+ (1− Z)1− Z¯
1− pˆi ,
where Z¯ was the proportion of treated patients in the study sample.
A weighted regression of outcome on treatment was fitted using these weights and
the simulated data. Clustered analyses for both the Cox proportional hazard model and
the Fine-Gray model were applied to adjust for the correlation introduced by the repli-
cation in the weighting process. Clustered analysis of Cox proportional hazard models is
available in most of statistical packages. The clustered analysis of Fine-Gray model has
been proposed (113)and was performed to estimate the marginal eﬀect using the package
crrSC in R (114).
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The performance of the various estimation approaches were evaluated through several
measures: the bias of the estimator from the true marginal treatment eﬀect, the mean
squared error (MSE) and the percent coverage (% coverage) of the nominal 0.95 con-
fidence intervals. All performance measures were averaged over the 1,000 replications.
Two diﬀerent sample sizes, 500 and 2000, were used for each simulated sample.
2.2.6 Propensity-based estimation of the treatment eﬀect in a case study
The five diﬀerent models described above were also applied to the post-MI cohort to
evaluate the marginal treatment eﬀects of statins on three diﬀerent cardiovascular out-
comes (MI, heart failure, and stroke) and all-cause mortality in the presence of competing
events. The PS was estimated using the covariates listed in Section 1.4.
2.3 Monte Carlo simulation results
2.3.1 True marginal treatment eﬀects
The true marginal treatment eﬀects for the three scenarios of competing risks are
summarized in Table 2.1. The true marginal treatment eﬀects decreased inversely to the
proportion of the event of interest in both hazard models.
Table 2.1: True marginal treatment eﬀect
proportion of ε=1
Model 0.4 0.6 0.8
subdistribution hazard -0.420 -0.390 -0.373
cause-specific hazard -0.426 -0.392 -0.384
2.3.2 Propensity-based estimation performance
The results obtained from the simulations for the four marginal models and one
conditional model are summarized in Table 2.2 and Table 2.3. The PS distributions
under the four diﬀerent KS distances considered are shown in Figure 2.1.
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Figure 2.1: Density plots of treated and untreated group in four scenarios
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Table 2.2: Simulation results of marginal treatment eﬀect using competing risks (sample size =500)
p=0.4 p=0.6 p=0.8
βˆ Var(βˆ) E(V) bias MSE %co. βˆ Var(βˆ) E(V) bias MSE %co. βˆ Var(βˆ) E(V) bias MSE %co.
K-S=0.10
SH crude -0.406 0.027 0.026 0.014 0.027 0.940 -0.379 0.019 0.018 0.011 0.019 0.940 -0.363 0.014 0.014 0.010 0.014 0.960
cru. CS -0.409 0.027 0.026 0.011 0.027 0.940 -0.381 0.018 0.019 0.009 0.018 0.950 -0.365 0.014 0.015 0.008 0.014 0.960
IPTW -0.439 0.023 0.027 -0.019 0.023 0.960 -0.410 0.015 0.020 -0.020 0.016 0.980 -0.391 0.010 0.015 -0.018 0.011 0.980
STW -0.414 0.025 0.026 0.005 0.025 0.960 -0.387 0.017 0.019 0.003 0.017 0.960 -0.371 0.013 0.015 0.002 0.013 0.970
Conv. -0.521 0.028 0.027 -0.101 0.039 0.910 -0.511 0.020 0.019 -0.122 0.035 0.870 -0.513 0.014 0.015 -0.140 0.034 0.810
CSH crude -0.395 0.030 0.028 0.031 0.031 0.940 -0.369 0.020 0.018 0.023 0.020 0.940 -0.352 0.015 0.013 0.032 0.016 0.930
cru. CS -0.398 0.030 0.029 0.028 0.031 0.950 -0.372 0.019 0.019 0.020 0.020 0.940 -0.355 0.014 0.014 0.029 0.015 0.940
IPTW -0.417 0.028 0.030 0.009 0.028 0.960 -0.392 0.017 0.020 -0.000 0.017 0.960 -0.378 0.012 0.014 0.006 0.012 0.970
STW -0.412 0.027 0.030 0.014 0.028 0.960 -0.387 0.017 0.019 0.005 0.017 0.960 -0.373 0.012 0.014 0.011 0.012 0.960
Conv. -0.511 0.034 0.031 -0.085 0.041 0.910 -0.511 0.022 0.020 -0.119 0.036 0.860 -0.514 0.017 0.014 -0.130 0.034 0.790
K-S=0.25
SH crude -0.262 0.026 0.025 0.158 0.051 0.810 -0.241 0.018 0.018 0.149 0.040 0.790 -0.233 0.014 0.014 0.140 0.033 0.790
cru. CS -0.277 0.025 0.026 0.143 0.046 0.840 -0.254 0.018 0.019 0.135 0.037 0.840 -0.246 0.013 0.015 0.127 0.030 0.830
IPTW -0.450 0.026 0.031 -0.030 0.027 0.960 -0.421 0.018 0.022 -0.031 0.019 0.980 -0.405 0.013 0.018 -0.032 0.014 0.980
STW -0.352 0.025 0.028 0.068 0.029 0.940 -0.327 0.017 0.021 0.062 0.021 0.940 -0.315 0.012 0.016 0.058 0.016 0.960
Conv. -0.510 0.031 0.029 -0.090 0.039 0.910 -0.502 0.023 0.021 -0.112 0.035 0.870 -0.507 0.016 0.016 -0.134 0.034 0.830
CSH crude -0.279 0.031 0.029 0.147 0.052 0.840 -0.256 0.019 0.019 0.136 0.037 0.830 -0.286 0.035 0.034 0.098 0.044 0.910
cru. CS -0.291 0.031 0.030 0.135 0.049 0.860 -0.268 0.019 0.019 0.124 0.034 0.850 -0.298 0.035 0.035 0.086 0.042 0.930
IPTW -0.433 0.033 0.035 -0.007 0.033 0.960 -0.407 0.019 0.023 -0.015 0.020 0.960 -0.444 0.038 0.041 -0.060 0.042 0.950
STW -0.413 0.032 0.035 0.013 0.032 0.970 -0.388 0.019 0.022 0.004 0.019 0.960 -0.425 0.037 0.040 -0.041 0.038 0.950
Conv. -0.512 0.038 0.034 -0.086 0.045 0.910 -0.509 0.022 0.021 -0.117 0.036 0.880 -0.513 0.042 0.039 -0.129 0.059 0.890
K-S=0.40
SH crude -0.640 0.027 0.028 -0.221 0.075 0.740 -0.595 0.020 0.019 -0.205 0.062 0.700 -0.566 0.016 0.015 -0.193 0.053 0.660
cru. CS -0.599 0.028 0.029 -0.179 0.060 0.830 -0.554 0.020 0.021 -0.165 0.047 0.800 -0.527 0.016 0.016 -0.154 0.040 0.790
IPTW -0.429 0.046 0.048 -0.009 0.046 0.960 -0.389 0.031 0.034 0.001 0.031 0.960 -0.375 0.022 0.026 -0.002 0.022 0.970
STW -0.474 0.042 0.044 -0.055 0.045 0.950 -0.433 0.028 0.031 -0.043 0.030 0.950 -0.415 0.020 0.024 -0.042 0.022 0.960
Conv. -0.524 0.038 0.036 -0.104 0.048 0.920 -0.511 0.028 0.025 -0.121 0.042 0.880 -0.509 0.021 0.020 -0.136 0.039 0.830
CSH crude -0.588 0.027 0.028 -0.162 0.053 0.850 -0.557 0.018 0.018 -0.165 0.045 0.780 -0.536 0.013 0.014 -0.152 0.037 0.770
cru. CS -0.555 0.028 0.030 -0.129 0.045 0.910 -0.524 0.019 0.020 -0.132 0.036 0.850 -0.503 0.014 0.015 -0.119 0.028 0.850
IPTW -0.422 0.043 0.048 0.004 0.043 0.960 -0.386 0.029 0.032 0.006 0.029 0.960 -0.368 0.021 0.023 0.016 0.021 0.960
STW -0.434 0.041 0.046 -0.008 0.041 0.960 -0.398 0.027 0.030 -0.006 0.027 0.970 -0.379 0.019 0.022 0.005 0.020 0.970
Conv. -0.525 0.040 0.038 -0.099 0.049 0.920 -0.516 0.027 0.025 -0.124 0.042 0.870 -0.515 0.020 0.018 -0.131 0.037 0.840
K-S=0.55
SH crude -0.744 0.030 0.028 -0.324 0.134 0.510 -0.691 0.020 0.019 -0.302 0.111 0.410 -0.658 0.014 0.015 -0.285 0.095 0.360
cru. CS -0.665 0.031 0.031 -0.245 0.091 0.710 -0.614 0.022 0.022 -0.224 0.072 0.690 -0.585 0.015 0.017 -0.212 0.060 0.650
IPTW -0.434 0.097 0.077 -0.014 0.097 0.920 -0.398 0.065 0.056 -0.008 0.065 0.940 -0.377 0.047 0.044 -0.004 0.047 0.960
STW -0.477 0.090 0.071 -0.057 0.094 0.920 -0.437 0.059 0.052 -0.047 0.062 0.940 -0.414 0.042 0.040 -0.040 0.044 0.960
Conv. -0.524 0.044 0.041 -0.104 0.055 0.910 -0.509 0.031 0.029 -0.119 0.045 0.880 -0.511 0.024 0.023 -0.138 0.043 0.840
CSH crude -0.675 0.031 0.028 -0.249 0.093 0.670 -0.647 0.019 0.018 -0.255 0.084 0.510 -0.631 0.013 0.014 -0.247 0.074 0.440
cru. CS -0.613 0.032 0.031 -0.187 0.067 0.820 -0.583 0.019 0.020 -0.191 0.055 0.720 -0.564 0.014 0.015 -0.180 0.047 0.690
IPTW -0.419 0.073 0.067 0.007 0.073 0.950 -0.405 0.048 0.046 -0.013 0.048 0.950 -0.382 0.035 0.037 0.002 0.035 0.970
STW -0.433 0.069 0.063 -0.007 0.069 0.950 -0.417 0.046 0.044 -0.025 0.046 0.950 -0.393 0.033 0.035 -0.009 0.033 0.970
Conv. -0.508 0.044 0.043 -0.082 0.051 0.930 -0.511 0.028 0.028 -0.119 0.042 0.900 -0.514 0.021 0.021 -0.130 0.038 0.860
p=proportion of ε=1, βˆ=estimator, Var(βˆ)= empirical variance, E(V)=average variance, SH=subdistribution hazard function,
CSH=cause-specific hazard function, conv.=conventional model Crude = Crude model: λ1(t|Z) = λ0(t)exp{βZ} ,Cru.-CS= crude model under common support ,
IPTW= weighted model by IPTW, STW=weighted model by stabilized weighted,Conv.=conventional model.
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Table 2.3: Simulation results of marginal treatment eﬀect using competing risks (sample size =2000)
p=0.4 p=0.6 p=0.8
βˆ Var(βˆ) E(V) bias MSE %co. βˆ Var(βˆ) E(V) bias MSE %co. βˆ Var(βˆ) E(V) bias MSE %co.
K-S=0.10
SH crude -0.398 0.006 0.006 0.022 0.007 0.950 -0.376 0.004 0.005 0.013 0.004 0.960 -0.358 0.003 0.004 0.015 0.003 0.950
cru. CS -0.398 0.006 0.006 0.022 0.007 0.960 -0.377 0.004 0.005 0.013 0.004 0.960 -0.358 0.003 0.004 0.015 0.003 0.950
IPTW -0.430 0.006 0.007 -0.010 0.006 0.970 -0.406 0.004 0.005 -0.016 0.004 0.970 -0.386 0.003 0.004 -0.013 0.003 0.980
STW -0.401 0.006 0.006 0.019 0.006 0.960 -0.380 0.004 0.005 0.010 0.004 0.960 -0.361 0.003 0.004 0.012 0.003 0.960
Conv. -0.502 0.007 0.007 -0.082 0.013 0.830 -0.502 0.005 0.005 -0.113 0.017 0.620 -0.501 0.003 0.004 -0.128 0.020 0.450
CSH crude -0.395 0.007 0.007 0.031 0.008 0.930 -0.372 0.004 0.005 0.020 0.005 0.940 -0.349 0.003 0.003 0.035 0.005 0.910
cru. CS -0.395 0.007 0.007 0.031 0.007 0.940 -0.372 0.004 0.005 0.020 0.005 0.950 -0.349 0.003 0.003 0.035 0.004 0.910
IPTW -0.418 0.007 0.007 0.008 0.007 0.970 -0.396 0.004 0.005 -0.004 0.004 0.980 -0.374 0.003 0.004 0.010 0.003 0.980
STW -0.412 0.006 0.007 0.014 0.006 0.960 -0.391 0.004 0.005 0.001 0.004 0.980 -0.370 0.003 0.003 0.014 0.003 0.980
Conv. -0.502 0.008 0.007 -0.076 0.013 0.850 -0.504 0.005 0.005 -0.112 0.017 0.630 -0.502 0.004 0.004 -0.118 0.018 0.500
K-S=0.25
SH crude -0.263 0.007 0.006 0.157 0.031 0.480 -0.245 0.005 0.005 0.145 0.025 0.420 -0.231 0.004 0.004 0.142 0.024 0.340
cru. CS -0.267 0.007 0.006 0.153 0.030 0.500 -0.249 0.005 0.005 0.141 0.024 0.460 -0.235 0.003 0.004 0.138 0.022 0.360
IPTW -0.449 0.007 0.007 -0.029 0.007 0.950 -0.423 0.004 0.005 -0.033 0.005 0.960 -0.401 0.003 0.004 -0.028 0.004 0.970
STW -0.343 0.006 0.007 0.077 0.012 0.860 -0.323 0.004 0.005 0.067 0.009 0.860 -0.305 0.003 0.004 0.068 0.008 0.840
Conv. -0.505 0.007 0.007 -0.085 0.014 0.830 -0.502 0.005 0.005 -0.113 0.018 0.640 -0.500 0.004 0.004 -0.126 0.020 0.480
CSH crude -0.398 0.007 0.007 0.028 0.007 0.930 -0.377 0.005 0.004 0.015 0.005 0.940 -0.358 0.003 0.003 0.026 0.004 0.920
cru. CS -0.398 0.007 0.007 0.028 0.008 0.930 -0.376 0.005 0.004 0.016 0.005 0.940 -0.357 0.003 0.003 0.027 0.004 0.920
IPTW -0.413 0.007 0.008 0.013 0.007 0.960 -0.391 0.004 0.005 0.001 0.004 0.960 -0.370 0.003 0.004 0.014 0.003 0.960
STW -0.412 0.007 0.008 0.014 0.007 0.960 -0.390 0.004 0.005 0.002 0.004 0.960 -0.369 0.003 0.004 0.015 0.003 0.950
Conv. -0.501 0.008 0.008 -0.075 0.014 0.860 -0.503 0.006 0.005 -0.111 0.018 0.650 -0.500 0.004 0.004 -0.116 0.017 0.510
K-S=0.40
SH crude -0.628 0.007 0.007 -0.208 0.050 0.290 -0.594 0.005 0.005 -0.204 0.047 0.170 -0.566 0.004 0.004 -0.193 0.041 0.120
cru. CS -0.610 0.007 0.007 -0.190 0.043 0.370 -0.576 0.005 0.005 -0.187 0.040 0.240 -0.549 0.004 0.004 -0.176 0.035 0.190
IPTW -0.412 0.011 0.012 0.008 0.011 0.960 -0.386 0.007 0.008 0.004 0.007 0.970 -0.368 0.005 0.006 0.006 0.005 0.970
STW -0.465 0.010 0.011 -0.045 0.012 0.940 -0.436 0.006 0.008 -0.047 0.008 0.940 -0.416 0.005 0.006 -0.043 0.007 0.940
Conv. -0.501 0.009 0.009 -0.081 0.015 0.860 -0.499 0.006 0.006 -0.110 0.018 0.700 -0.500 0.005 0.005 -0.127 0.021 0.550
CSH crude -0.583 0.007 0.007 -0.157 0.032 0.560 -0.560 0.005 0.005 -0.168 0.033 0.290 -0.537 0.004 0.003 -0.153 0.027 0.260
cru. CS -0.569 0.007 0.007 -0.143 0.028 0.630 -0.545 0.005 0.005 -0.153 0.028 0.380 -0.522 0.004 0.003 -0.138 0.023 0.350
IPTW -0.398 0.011 0.012 0.028 0.012 0.950 -0.377 0.006 0.008 0.015 0.007 0.960 -0.356 0.004 0.006 0.028 0.005 0.960
STW -0.413 0.010 0.011 0.013 0.011 0.960 -0.391 0.006 0.007 0.001 0.006 0.970 -0.369 0.004 0.006 0.015 0.004 0.980
Conv. -0.503 0.009 0.009 -0.077 0.015 0.870 -0.507 0.006 0.006 -0.115 0.019 0.690 -0.503 0.004 0.004 -0.119 0.019 0.570
K-S=0.55
SH crude -0.732 0.007 0.007 -0.312 0.104 0.030 -0.693 0.005 0.005 -0.303 0.097 0.010 -0.663 0.004 0.004 -0.290 0.088 0.000
cru. CS -0.693 0.007 0.007 -0.273 0.082 0.090 -0.656 0.005 0.005 -0.266 0.076 0.040 -0.627 0.004 0.004 -0.254 0.068 0.020
IPTW -0.406 0.020 0.022 0.014 0.020 0.960 -0.388 0.015 0.016 0.002 0.015 0.960 -0.373 0.012 0.012 -0.000 0.012 0.960
STW -0.455 0.017 0.020 -0.035 0.019 0.950 -0.431 0.013 0.014 -0.041 0.015 0.940 -0.413 0.010 0.010 -0.040 0.012 0.930
Conv. -0.497 0.010 0.010 -0.078 0.016 0.870 -0.499 0.007 0.007 -0.109 0.019 0.760 -0.506 0.006 0.006 -0.133 0.024 0.580
CSH crude -0.672 0.007 0.007 -0.246 0.067 0.150 -0.641 0.005 0.005 -0.249 0.067 0.030 -0.622 0.003 0.003 -0.238 0.060 0.020
cru. CS -0.642 0.007 0.007 -0.216 0.054 0.290 -0.610 0.005 0.005 -0.218 0.052 0.100 -0.590 0.003 0.004 -0.206 0.046 0.070
IPTW -0.398 0.019 0.020 0.028 0.020 0.960 -0.374 0.012 0.013 0.018 0.012 0.960 -0.358 0.009 0.010 0.026 0.010 0.960
STW -0.414 0.018 0.019 0.012 0.018 0.960 -0.388 0.011 0.013 0.004 0.011 0.960 -0.371 0.008 0.010 0.013 0.009 0.970
Conv. -0.503 0.010 0.010 -0.077 0.016 0.880 -0.502 0.007 0.007 -0.110 0.019 0.730 -0.503 0.005 0.005 -0.119 0.019 0.620
p=proportion of ε=1, βˆ=estimator, Var(βˆ)= empirical variance, E(V)=average variance, SH=subdistribution hazard function,
CSH=cause-specific hazard function, conv.=conventional model Crude = Crude model: λ1(t|Z) = λ0(t)exp{βZ} ,Cru.-CS= crude model under common support ,
IPTW= weighted model by IPTW, STW=weighted model by stabilized weighted,Conv.=conventional model.
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As shown in Table 2.2 and Table 2.3, the model adjusted by weighed methods, either
IPTW or STW, had the highest percent of true estimator coverage and the least amount
of bias under all scenarios considered. The percent of true value coverage of the weighted
model was higher than 95% for all scenarios. The bias-variance trade-oﬀ can be observed
in weighted models, however, the percent coverage of both weighted methods were close.
In the weighted model, the bigger amount of bias showed with the larger KS distance.
The two weighted regressions also performed better than the other models when sample
sizes were smaller. In situations with a low occurrence of the event of interest and a large
KS distance, the estimators of the weighted methods had variances remarkably diﬀerent
from the other models. In the IPTW model and KS =0.55, the variance estimator from
the model based approach was reduced by 80% when using the bootstrapping method.
In the STW, variance from bootstrapping method was reduced to 60% with the same
KS.
For the crude model, which is unadjusted, the marginal treatment eﬀects can be
estimated from a randomized study. However, the same model, used in an observational
study where confounding variables are present, may result in a biased estimator. As the
level of confounding increases, the bias increases. In this study, the crude models were
more sensitive than the weighted models to the level of confounding as measured by KS
distance. When the KS distance increased from 0.1 to 0.55, the amount of bias increased
less than three times for the weighted estimators. In comparison to the crude model, the
crude model under common support showed improved eﬃciency in terms of bias, MSE
and percent coverage.
The conventional model, which yielded estimators of the conditional treatment eﬀects
by including all confounding in the model, was shown to be a poor estimator of the
marginal treatment eﬀects. The estimators from the conventional model were more stable
than the other models when the confounding level increased. However, the estimator from
conventional model may not be the true causal estimator.
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2.4 Case study results
In the study of statin treatment eﬀects in the elderly who experienced myocardial
infarction, randomization was unethical and the mortality event highly competed other
cardiovascular disease outcomes. The cardiovascular outcomes of interest were MI, HF
and stroke while all-cause mortality was a competing event. A total of 71,030 patients
from the Medicare claims data were included in the analysis, and 64.5% of them received
statins after discharge. As presented in Table 2.4, the unadjusted percentage of patients
that had the occurrence of MI, mortality, stroke and heart failure were lower in the statin
users group. All cause mortality constituted the highest percentage among observed
events in both statin user and non-user groups.
Table 2.4: Number and percent of observed outcomes
Survived Mortality MI stroke heart failure
Non-statins number 14529 5749 2812 506 1643
percent 57.6 22.8 11.1 2.0 6.5
Statins number 31509 6318 4415 831 2718
percent 68.8 13.8 9.6 1.8 5.9
For the PS estimated using a logistic regression, the strong predictors for the proba-
bility of receiving statin treatment were baseline statins (αˆ= 1.66), admission for CABG
(αˆ=0.68), admission for stent/PTCA (αˆ=0.66), beta blocker users (αˆ=0.99) and moder-
ate to severe liver disease (αˆ=-0.58). Those variables were consistent with the indications
for treatment with statins (56, 52, 101) The KS distance between the PS distribution of
statin users and non-statin user was 0.418, and the c statistics was 0.767.
As shown in Table 2.5, the unadjusted crude model showed large marginal treatment
eﬀects for all outcomes, indicating bias in non-experimental studies. The results from
crude model showed that statins significantly reduced the risk of recurrent MI, stroke,
heart failure and all cause mortality. The use of the IPTW resulted in a large amount of
weighting, the maximum weighting was 46. The weighted models, which were expected
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to show a good eﬃciency for the estimator, did not show a significant eﬀect for statins
for statins for reducing the risk of stroke or recurrent MI, but did show that statins
significantly reduced the risk of HF and all-cause mortality. IPTW and STW methods
showed an inconsistency when the event was recurrent MI.
The estimated statin treatment eﬀects for stroke from STW presented diﬀerent results
for the Fine-Gray model and the Cox proportional hazard model. The estimators from
the cause-specific hazard function were larger than subdistribution hazard function for
all outcomes. In addition, the estimator from the cause-specific hazard function can
be overestimated when summarized from the competing risks survival model with the
cumulative incidence function. The estimators from applying STW to subdistribution
hazard function seem to be reasonable to use for the marginal treatment eﬀects for this
data.
To account for the large variance resulting from the low occurrence of event of interest
and the great separation in the propensity score distributions, a bootstrapping method
was used to obtain variance estimates. With this approach, the variance of the estima-
tors were decreased to 40% and 20% of the model-based sandwich variance estimator for
IPTW and STW methods, respectively (Table 2.6). As a result, the eﬀect estimate for
MI and heart failure from the IPTW model changed from non-significant to significant
(α = 0.05). STW also showed a diﬀerent result, in terms of significance of eﬀect, for the
stroke endpoint. This finding of the large reduction in variances observed here has not
been described previously. This may be due, in part, to the large number of confounders
being adjusted for in the propensity score. In general, greater reductions in variance can
be expected from larger propensity score models.
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Table 2.5: The treatment eﬀects of statins for elderly who were hospitalized for an AMI
subdistribution model cause-specific model
Failure βˆ SE p-value βˆ SE p-value
MI Crude -0.153 0.024 0.000 -0.222 0.024 0.000
Crude-CS -0.153 0.024 0.000 -0.222 0.024 0.000
IPTW∗ 0.041 0.016 0.011 0.039 0.016 0.017
STW∗ 0.003 0.024 0.905 -0.010 0.024 0.676
Conv. -0.003 0.027 0.900 -0.021 0.027 0.440
All-cause Crude -0.553 0.018 0.000 -0.581 0.018 0.000
mortality Crude-CS -0.553 0.018 0.000 -0.581 0.018 0.000
IPTW∗ -0.045 0.013 0.001 -0.042 0.014 0.002
STW∗ -0.126 0.018 0.000 -0.129 0.018 0.000
Conv. -0.132 0.021 0.000 -0.130 0.021 0.000
Stroke Crude -0.101 0.056 0.075 -0.196 0.056 0.001
Crude-CS -0.101 0.056 0.074 -0.196 0.056 0.001
IPTW∗ -0.056 0.036 0.125 -0.057 0.036 0.116
STW∗ -0.097 0.053 0.068 -0.112 0.053 0.034
Conv. -0.095 0.063 0.130 -0.112 0.063 0.075
HF Crude -0.095 0.031 0.002 -0.176 0.031 0.000
Crude-CS -0.095 0.031 0.002 -0.176 0.031 0.000
IPTW∗ -0.067 0.022 0.003 -0.065 0.022 0.003
STW∗ -0.077 0.032 0.016 -0.088 0.032 0.006
Conv. -0.048 0.035 0.170 -0.066 0.035 0.059
*Standard error estimated from bootstrapping method
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Table 2.6: Comparison of the variance of the model-base sandwich and bootstrapping
method
subdistribution hazard cause-specific hazard
βˆ SE p-value % reduc. βˆ SE p-value % reduc.
IPTW MI model 0.041 0.031 0.186 0.039 0.031 0.208
boots. 0.040 0.016 0.012 73.4 0.038 0.016 0.018 73.4
Death model -0.045 0.023 0.050 -0.042 0.023 0.068
boots. -0.044 0.013 0.001 68.1 -0.058 0.014 0.000 62.9
Stroke model -0.056 0.070 0.424 -0.057 0.070 0.415
boots. -0.057 0.036 0.113 73.6 -0.058 0.036 0.107 73.6
HF model -0.067 0.040 0.094 -0.065 0.041 0.113
boots. -0.068 0.022 0.002 69.8 -0.067 0.022 0.002 71.2
STW MI model 0.003 0.030 0.920 -0.010 0.030 0.739
boots. 0.005 0.024 0.835 36.0 -0.008 0.024 0.739 36.0
Death model -0.126 0.023 0.000 -0.129 0.023 0.000
boots. -0.125 0.018 0.000 38.8 -0.127 0.018 0.000 38.8
Stroke model -0.097 0.068 0.154 -0.112 0.068 0.100
boots. -0.098 0.053 0.064 39.3 -0.113 0.053 0.033 39.3
HF model -0.077 0.039 0.048 -0.088 0.039 0.024
boots. -0.077 0.032 0.016 32.7 -0.088 0.032 0.006 32.7
βˆ=treatment eﬀect estimator,
%reduc. = percent of variance reduction from model-base variance
model=model-base sandwich variance estimator, boots=bootstrapping variance estimator
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2.5 Discussion
In this study we examined the performance of propensity score-based methods in the
presence of competing risks . Two hazard functions for competing risk methods were
considered: the cause-specific hazard function and the subdistribution hazard function.
Two weighting methods, IPTW and STW were shown to have the smallest amount of
bias and the highest percent coverage compared to other models. The advantage of the
STW method had over the IPTW methods shown in Xu et al (111) for conventional
linear regression models was not clearly exhibited for the competing risks model in this
study. Suarez et al (99) examined the diﬀerences between marginal structural models
(MSMs) and conventional models and found that the estimators from MSMs had a 20%
diﬀerence in eﬀect size from a conventional model, but MSMs estimators had a 19%
larger standard error. This study also saw inflated variances in the weighted models in
comparison with the conventional model and the crude models. This inflation was more
pronounced when the occurrence of the event of interest was low and the separation
between propensity score distributions of the two treatment groups was high. Hahn (36)
demonstrated that PS does not decrease the asymptotic variance bound when estimating
average treatment eﬀect. In this situation, the bootstrapping method is recommended
to obtain the variance.
The estimates for the true marginal treatment eﬀect calculated from the random-
ization trial simulation were not equal to the true parameters specified in the setup of
simulations. This was due to the non-collapsibility characteristic of estimators from non-
linear models. The conventional conditional model yielded greater biases in the eﬀect
estimator due to the same non-collapsibility of estimators from nonlinear models. The
marginal treatment eﬀects from nonlinear models, such as survival analysis, are usually
closer to the null compared to a conditional model (71). It is also possible that there
was an imbalance in the data. Gail et al (25) showed that the estimator from unadjusted
analyses of randomized trials could be biased when important variables were not well
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controlled. It is similar to the situation where the assumption of no model misspecifi-
cation was violated in MSMs. In order to obtain an unbiased estimator, one needs an
excellent knowledge of confounders and risk factors for the question of interest. Our
analyses were limited to data available in Medicare claims, which may not capture all
potential risk factors.
The KS distance was used to characterize the diﬀerences between density functions of
the propensity scores of the two treatment groups. The KS distance increases when the
confounding variables are highly predictive of the probability of receiving treatment. In
simulations presented in this study, eﬃciency of estimators decreased as the KS distance
increased, which also produced an increase in bias and a decrease in percent coverage.
We chose KS distance as a measure of confounding for several reasons. In studies using
propensity score methods, c-statistics are widely used to show how well the propensity
score model can discriminate between treatment groups (46). Westreich (107) demon-
strated that higher values of the c-statistics may be associated with less overlap of propen-
sity score distributions between the treated and untreated groups. Austin et al (5) found
that c-statistics has no association with the ability of propensity scores to balance con-
founding factors between the treated and untreated groups when matching methods were
used. In comparison, the KS distance is based on the empirical distribution function,
and the supremum of absolute diﬀerences between the empirical distribution of treated
and untreated is reported (63). We thus believe the KS distance is a better measure for
this study.
Our findings should be interpreted in light of some limitations. This study consid-
ered a relatively small number of dichotomous confounding factors in the simulations.
In practice, the number of confounding factors in observational studies can be large,
the confounding factors may be continuous (such as age), and continuous confounding
factors increase the chance of model misspecification. Further investigations are needed
to evaluate the performances of these models when continuous confounding variables are
present.
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In conclusion, the weighted methods, IPTW and STW, could be used to control for
confounding when conducting competing risk analyses to estimate the marginal treatment
eﬀects. Appropriate variance estimation approaches are needed when the frequency of
the event of interest is low and the distance between propensity score distributions of the
two treatment groups are high. In this situation, a bootstrapping method can be used
to obtain variance estimates which appropriately take advantage of the estimation of the
propensity score.
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Chapter 3
Conditional Treatment Eﬀects of Competing Risks Models
3.1 Introduction
A conditional treatment eﬀect is the average eﬀect of treatment on the individual.
Non-experimental studies are increasingly used to evaluate the eﬀect of treatments on
outcomes, especially for medications that have been released on the market (11). In
these studies, the treatment choice is often influenced by the characteristics of patients,
and this may lead to confounding due to characteristics present in patients before the
treatment choice is made that may influence both the choice and future events (96).
Therefore, in order to obtain a valid estimate of the treatment eﬀect on outcomes, one
must account for these systematic diﬀerences.
Multivariable regression adjustment has been widely used to control for confounding
by including potentially confounding baseline covariates in the outcome model. Recently,
methods based on PS have been increasingly used to control for confounding in estimation
of the treatment eﬀects in non-experimental studies. Such approaches may be used to
obtain unbiased estimates of adjusted treatment eﬀects from regression models (which
include confounding variables also present in the PS models) as well as the marginal
treatment eﬀects discussed in Chapter 2.
The performances of PS methods have been investigated in both Monte Carlo simula-
tions and systematic reviews. When applied to linear regression, the PS methods showed
similar or better results as a multivariate regression (88, 89, 70). Using PS methods
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with logistic regression leads to better control of imbalances between treatment groups
than conventional logistic regression provides when the event to confounder ratio is less
than 7:1 (14). In time-to-event analyses where PS methods were applied to Cox pro-
portional hazard models, the PS pair-matching method had the smallest amount of bias
compared to other methods (26, 4). PS matching and subclassification yielded a larger
treatment eﬀect compared to conventional Cox proportional hazard models (62). Little
has been done to evaluate the performance of PS methods when used with competing
risks analyses.
Competing risk methods extend the applicability of survival analysis to situations
where there are multiple outcome events but only the first occurring event for each sub-
ject is observable. These methods are being increasingly used in studies where competing
events are likely to occur. However, competing risk models conventionally use multivari-
able adjustment, including all the covariates in the outcome model, which is not suitable
in studies where the outcome of interest is rare and a large number of confounders are
present (11). It was natural to consider applying PS methods to reduce or diminish the
eﬀect of confounding in competing risks analysis. This study aimed to investigate the
performance of PS methods to estimate conditional treatment eﬀects when applied to
competing risks analyses where a large number of confounders are present.
3.2 Methods
3.2.1 Monte Carlo simulation
We conducted a series of Monte Carlo simulations in order to examine the perfor-
mance of several PS methods with two competing risk models for estimating conditional
treatment eﬀects: the subdistribution hazard model and the cause-specific hazard model.
Let Zn×1 be the matrix of binary treatment, Z ∈ {0, 1}, where z=1 if treated and
z=0 if untreated. Let Xn×l T be the matrix of confounding variables with sample size
n ∈ {500, 1000, 2000} and l numbers of confounding variables l ∈ {5, 15, 50, 100}.
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The set of confounders consisted of both binary and continuous variables. The binary
confounding were generated from a Bernoulli distribution with parameter p = 0.5. The
continuous confounding variables were generated from a normal distribution with zero
mean and unit variance. The total number of confounding variables dictated the number
of continuous variables that were generated: for a total of 5 or 15, one continuous variable
was generated; for a total of 50 confounders, 3 continuous variables were generated; for
a total of 100, 5 variables were generated.
The probability that the exposure was equal to one, which is the true PS, was gen-
erated as a function of the confounding. The vector Z was drawn from a Bernoulli
distribution with probability set by
logit(θ) = α0 + ΣlαlXl
where θ is the probability to receive treatment, and αl are parameters for covariates
included in the PS model. The values of α were fixed at levels such that the distance
between PS distributions of the treated and untreated group measured by KS distance
was equal to 0.2.
Two types of hazard model used in competing risks analysis were considered: cause-
specific hazard function (51) and subdistribtion hazard function (30). Failure times were
generated using the two hazard functions given the presence of competing events using
methods similar to those presented in Chapter 2. Two types of observing event and the
proportion of the event of interest was 0.6. The true treatment eﬀects (β) on the outcome
considered were 0 for the null model and -0.5 for the alternative model. The censored
data (Ci) were generated from a uniform distribution to generate 20% of censoring.
3.2.2 Propensity-based estimation of the treatment eﬀect in simulations
For each simulated dataset, five diﬀerent models were fitted with the two diﬀerent
competing risk analysis approaches: PS matching, PS matching under common support
area, subclassification, PS adjustment in the model.
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3.2.2.1 PS matching
PS matching methods attempt to choose a single or multiple patients from the un-
treated group with the same values of the PS variable for each patient in the treated
group. There are three ways to implement PS matching: pair matching (one-to-one
matching), many-to-one matching and full matching. Pair matching method is the most
common method for PS matching. Full matching includes all subjects and groups them to
their best matching sets. This method reduces bias more eﬀectively than pair matching
and result in closer matches than many-to-one matching (37). Full matching results in
matched sets consisting at least one treated and at least one untreated, thus potentially
creating a wide range of treated to untreated ratio (94).
In this simulation, we used full matching. The distance matrix was constructed from
rank based Mahalanobis distance and the caliper was 0.2×S.D of PS (79). The sample
was matched using two diﬀerent methods, the entire sample approach and the common
support approach. The common support approach included only subjects who fell under
the overlap area between PS distribution of the treated and untreated.
A stratified Cox model was applied to estimate the conditional treatment eﬀect with
the cause-specific hazard function. For the full matching method, the number of strata
increases as the sample size increases, which could impact the power of Cox model (103).
The cause-specific hazard function for the kth stratum is
hk(t, Z,X) = h0k(t)exp(βZ + γX)
Stratification for the Fine-Gray model was developed with two stratification regimes
, highly stratified and regular stratified (115). The highly stratification method applies
when the size of stratum is finite as n → ∞. The regular stratification method is used
when the number of strata is finite, a larger total sample size can produce larger sample
size in the stratum.
The subdistribution hazard function for the kth stratum (group of matching PS) is
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λk(t, Z) = λ0k(t)exp(βZ)
whereλ0k is the baseline hazard function for stratum k.
3.2.2.2 Subclassification
Subclassification is a method used to adjust for confounding factors by classifying the
treated and untreated into strata based on percentiles of PS. We used quintiles of PS,
as is generally done to divide the subjects into strata, to conduct subclassification. The
quintiles of PS can remove approximately 90% of the initial bias due to confounding (81).
For the cause-specific hazard function analysis, a stratified Cox model was employed
to estimate the treatment eﬀect. With this model, the baseline hazard function varies
by each subclass or stratum. The number of strata from subclassification is smaller than
the full PS matching used in Section 3.2.2.1, and it may have less impact on the sample
sizes and power of the Cox model.
The regular stratification method of the Fine-Gray model was applied to the subdis-
tribution hazard function data analysis (115).
3.2.2.3 Adjustment for PS in the model
Including PS adjustment in an outcome regression model is another standard PS
implementation method. This approach assumes a specific function form for the rela-
tionship of the PS to the outcome. Violation of this assumption can introduce a large
amount of bias when the covariance of the treated and untreated group are unequal (19).
For this study, a multivariable Cox model was used to estimate the treatment eﬀect
for the cause-specific hazard function and a multivariable Fine-Gray model was used to
estimate the treatment eﬀect for the subdistribution hazard function.
All analyses in this study were performed in R version 3.0.1 (102). The package
survival (103) was employed for the cause-specific hazard function. The packages cmprsk
(29) and crrSC (114) were used to analyze the data from the subdistribution hazard
41
function. The package optmatch (38) were used for PS matching. The performance of
the various estimation approaches were evaluated through several measures: the bias of
the estimator from the true treatment eﬀect, the mean squared error (MSE), power and
the percent coverage of the nominal 0.95 confidence intervals. All performance measures
were averaged over the 1,000 replications. Three diﬀerent sample sizes, 500, 100 and
2000 were used for each simulated sample. The null model and alternative model were
tested, the true treatment eﬀect for null model was fixed at 0 while true treatment eﬀect
for alternative model was fixed at -0.5.
3.2.3 Propensity-based estimation of the conditional treatment eﬀect in a
case study
The five diﬀerent models described above were also used with the dataset extracted
from the Medicare claims data of the elderly post-AMI cohort to evaluate the conditional
treatment eﬀects of statins on three diﬀerent cardiovascular outcomes (MI, HF, and
stroke) and all-cause mortality. The patients who died within 30 days after discharge
were excluded from the analysis. The patients were followed up from 31 days after
discharge until the occurrence of the first event: MI, stroke, HF or death.
The PS was estimated in a logistic regression model using a list of 134 covariates
identified a priori, including baseline demographics, comorbidities, medications, proce-
dures, current cormorbidities, medication and diagnoses during admission, interaction
terms between age and group of total CCI also included in the PS model. Details of the
variables included in the model and estimators appear in Appendix 1.
The competing risks models, one using the subdistribution hazard function and the
other using the cause-specific hazard function, were applied to estimate treatment eﬀects
of statins on the risk of MI, stroke, HF and mortality. The R package was used to analyze
the data.
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3.3 Simulation results
The estimators for conditional treatment eﬀects under all considered scenarios are
summarized in Table 3.1- Table 3.4. The performance of the estimators was diﬀerent
for each of the following: diﬀerent numbers of confounding variables, the type of model
(null, alternative), and the hazard function (subdistribution, cause-specific). For smaller
numbers of confounding variables, the PS-based estimator’s performance was similar to
that from the conventional model.
PS methods yielded good eﬃciency for the estimator in the model with heavy con-
founding. In the scenario of small sample size and heavy confounding, the large variance
of the estimator from the conventional model was noticeable. In the scenario of heavy
confounding, the power of the estimator from the subdistribution hazard model was larger
than that from the cause-specific hazard model. The estimator from PS adjusted into
multivariate model presented a high percent coverage and small bias in the null model.
Subclassification methods showed the smallest MSE for alternative model with heavy
confounding.
3.3.1 Under the null model
The objective of simulations under a null model was to study the false negative
results. Estimators of covariate adjustment method using the PS performed the best and
presented the smallest bias, MSE and the highest percent coverage (> 95%) for both the
cause-specific hazard function and the subdistribution hazard function under all scenarios
considered.
For the PS subclassification method, high percent coverage and small MSE were
present under the cause-specific hazard function but not under the subdistribution haz-
ard function. Under the subdistribution hazard function, the percent coverage of the esti-
mators from PS subclassification method noticeably decreased with heavier confounding.
The PS matching estimators showed low percent coverage and a large MSE under all
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settings. Matching under the common support approach yielded estimators with minimal
improved eﬃciency for the treatment eﬀect for both types of hazard functions. Among
all methods, the PS matching estimators had the largest variance.
3.3.2 Under the alternative model
In the scenario of heavy confounding (50 and 100 confounder variables), estimator
from subclassification hazard model had small MSE and high power of the test. However,
those results did not show in the estimators from the cause-specific hazard model. For
the cause-specific hazard model, the conventional model presented a small bias, a small
MSE and a high percent coverage. For the non-heavy confounding (5 and 15 confounder
variables) the conventional model outperformed the other methods. The conventional
model estimators had a smaller bias, a smaller MSE and greater percent coverage for
both the subdistribution hazard function and the cause-specific hazard function.
For the estimators from the PS covariate adjustment method, although they per-
formed the best under the null model, they were shown to be the worst estimator for
the alternative models. The estimators from PS matching and matching under common
support showed the largest variance for all scenarios. In the scenario of small sample size
and heavy confounding (100 confounding variables), the performance of PS matching
improved, the estimator had the smallest bias and the highest percent coverage.
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Table 3.1: Simulation result of conditional model of 5 confounders
No. confounders=5 Subdistribution model Cause-specific model
Sample size β βˆ V(βˆ) E(V) bias MSE %cov. power βˆ V(βˆ) E(V) bias MSE %cov. power
500 CONV. 0.000 0.000 0.019 0.019 0.000 0.019 0.948 0.052 0.004 0.018 0.018 0.004 0.018 0.948 0.052
PS Adj. 0.000 0.000 0.017 0.019 0.000 0.017 0.962 0.038 0.003 0.016 0.018 0.003 0.016 0.962 0.038
Subclass 0.000 0.079 0.017 0.017 0.079 0.023 0.908 0.092 0.006 0.016 0.018 0.006 0.016 0.965 0.035
Matching 0.000 0.078 0.029 0.030 0.078 0.036 0.926 0.074 0.089 0.036 0.035 0.089 0.044 0.931 0.069
Match.-CS 0.000 0.079 0.031 0.031 0.079 0.037 0.923 0.077 0.072 0.037 0.037 0.072 0.043 0.939 0.061
CONV. -0.500 -0.505 0.024 0.023 -0.005 0.024 0.945 0.918 -0.498 0.021 0.021 0.002 0.021 0.950 0.942
PS Adj. -0.500 -0.467 0.022 0.023 0.033 0.023 0.952 0.887 -0.447 0.018 0.021 0.053 0.021 0.955 0.896
Subclass -0.500 -0.387 0.021 0.021 0.113 0.034 0.877 0.767 -0.443 0.019 0.021 0.057 0.022 0.947 0.888
Matching -0.500 -0.390 0.036 0.035 0.110 0.048 0.893 0.560 -0.375 0.039 0.041 0.125 0.055 0.910 0.475
Match.-CS -0.500 -0.388 0.039 0.036 0.112 0.051 0.887 0.531 -0.394 0.044 0.043 0.106 0.055 0.909 0.486
1000 CONV. 0.000 0.002 0.009 0.009 0.002 0.009 0.946 0.054 -0.001 0.009 0.009 -0.001 0.009 0.947 0.053
PS Adj. 0.000 0.001 0.008 0.009 0.001 0.008 0.963 0.037 -0.000 0.008 0.009 -0.000 0.008 0.968 0.032
Subclass 0.000 0.080 0.008 0.008 0.080 0.015 0.849 0.151 0.004 0.008 0.009 0.004 0.008 0.964 0.036
Matching 0.000 0.075 0.014 0.015 0.075 0.020 0.909 0.091 0.071 0.017 0.017 0.071 0.022 0.917 0.083
Match.-CS 0.000 0.079 0.014 0.015 0.079 0.020 0.910 0.090 0.071 0.017 0.018 0.071 0.022 0.923 0.077
CONV. -0.500 -0.497 0.011 0.011 0.003 0.011 0.955 -0.505 0.011 0.010 -0.005 0.011 0.949 0.999
PS Adj. -0.500 -0.461 0.009 0.011 0.039 0.011 0.954 0.998 -0.454 0.009 0.010 0.046 0.011 0.936 0.997
Subclass -0.500 -0.381 0.009 0.010 0.119 0.024 0.790 0.969 -0.450 0.009 0.010 0.050 0.012 0.928 0.996
Matching -0.500 -0.378 0.017 0.017 0.122 0.032 0.840 0.823 -0.398 0.020 0.020 0.102 0.030 0.892 0.819
Match.-CS -0.500 -0.381 0.017 0.018 0.119 0.031 0.858 0.820 -0.396 0.021 0.021 0.104 0.031 0.878 0.802
2000 CONV. 0.000 -0.003 0.005 0.005 -0.003 0.005 0.940 0.060 -0.001 0.009 0.009 -0.001 0.009 0.947 0.053
PS Adj. 0.000 -0.003 0.004 0.005 -0.003 0.004 0.948 0.052 -0.000 0.008 0.009 -0.000 0.008 0.968 0.032
Subclass 0.000 0.072 0.005 0.004 0.072 0.010 0.803 0.197 0.004 0.008 0.009 0.004 0.008 0.964 0.036
Matching 0.000 0.065 0.008 0.008 0.065 0.012 0.884 0.116 0.071 0.017 0.017 0.071 0.022 0.917 0.083
Match.-CS 0.000 0.073 0.008 0.008 0.073 0.014 0.855 0.145 0.071 0.017 0.018 0.071 0.022 0.923 0.077
CONV. -0.500 -0.506 0.005 0.006 -0.006 0.005 0.940 1 -0.505 0.011 0.010 -0.005 0.011 0.949 0.999
PS Adj. -0.500 -0.469 0.005 0.006 0.031 0.006 0.947 1 -0.454 0.009 0.010 0.046 0.011 0.936 0.997
Subclass -0.500 -0.392 0.005 0.005 0.108 0.017 0.682 1 -0.450 0.009 0.010 0.050 0.012 0.928 0.996
Matching -0.500 -0.394 0.009 0.009 0.106 0.020 0.797 0.991 -0.398 0.020 0.020 0.102 0.030 0.892 0.819
Match.-CS -0.500 -0.386 0.009 0.009 0.114 0.022 0.758 0.976 -0.396 0.021 0.021 0.104 0.031 0.878 0.802
β=treatment eﬀect, Var(βˆ)= empirical variance, E(V)=average variance,
CONV.=conventional model, PS adj.= Propensity score adjusted into the model, Subclass=subclassification,
Match.-CS= Matching under common support
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Table 3.2: Simulation result of conditional model of 15 confounders
No. confounders=15 Subdistribution model Cause-specific model
Sample size β βˆ V(βˆ) E(V) bias MSE %cov. power βˆ V(βˆ) E(V) bias MSE %cov. power
500 CONV. 0.000 0.003 0.018 0.017 0.003 0.018 0.944 0.056 -0.000 0.018 0.018 -0.000 0.018 0.943 0.057
PS Adj. 0.000 0.005 0.013 0.017 0.005 0.013 0.975 0.025 0.005 0.014 0.018 0.005 0.014 0.976 0.024
Subclass 0.000 0.039 0.015 0.015 0.039 0.016 0.936 0.064 0.007 0.014 0.018 0.007 0.014 0.973 0.027
Matching 0.000 0.035 0.028 0.030 0.035 0.030 0.952 0.048 0.039 0.038 0.038 0.039 0.039 0.948 0.052
Match.-CS 0.000 0.039 0.032 0.031 0.039 0.034 0.944 0.056 0.045 0.038 0.040 0.045 0.040 0.959 0.041
CONV. -0.500 -0.514 0.021 0.020 -0.014 0.021 0.944 0.950 -0.516 0.023 0.021 -0.016 0.024 0.941 0.941
PS Adj. -0.500 -0.409 0.015 0.020 0.091 0.024 0.921 0.867 -0.409 0.017 0.020 0.091 0.026 0.922 0.849
Subclass -0.500 -0.373 0.017 0.017 0.127 0.033 0.835 0.829 -0.408 0.018 0.021 0.092 0.026 0.922 0.833
Matching -0.500 -0.380 0.035 0.034 0.120 0.049 0.889 0.553 -0.391 0.041 0.044 0.109 0.053 0.929 0.450
Match.-CS -0.500 -0.373 0.035 0.035 0.127 0.051 0.892 0.522 -0.384 0.045 0.046 0.116 0.059 0.908 0.421
1000 CONV. 0.000 -0.001 0.009 0.008 -0.001 0.009 0.939 0.061 0.006 0.009 0.009 0.006 0.009 0.941 0.059
PS Adj. 0.000 0.000 0.006 0.008 0.000 0.006 0.974 0.026 0.009 0.007 0.009 0.009 0.007 0.976 0.024
Subclass 0.000 0.036 0.007 0.007 0.036 0.009 0.926 0.074 0.011 0.007 0.009 0.011 0.007 0.976 0.024
Matching 0.000 0.036 0.015 0.015 0.036 0.016 0.944 0.056 0.057 0.019 0.020 0.057 0.022 0.936 0.064
Match.-CS 0.000 0.042 0.015 0.016 0.042 0.017 0.945 0.055 0.056 0.020 0.020 0.056 0.023 0.929 0.071
CONV. -0.500 -0.510 0.010 0.010 -0.010 0.010 0.949 0.998 -0.503 0.011 0.010 -0.003 0.011 0.924 0.996
PS Adj. -0.500 -0.412 0.007 0.010 0.088 0.015 0.891 0.991 -0.405 0.009 0.010 0.095 0.018 0.863 0.986
Subclass -0.500 -0.375 0.009 0.009 0.125 0.024 0.735 0.979 -0.404 0.009 0.010 0.096 0.018 0.867 0.988
Matching -0.500 -0.382 0.016 0.017 0.118 0.030 0.861 0.841 -0.375 0.023 0.023 0.125 0.039 0.858 0.710
Match.-CS -0.500 -0.379 0.017 0.018 0.121 0.032 0.851 0.835 -0.379 0.022 0.023 0.121 0.037 0.871 0.729
2000 CONV. 0.000 -0.000 0.004 0.004 -0.000 0.004 0.939 0.061 0.002 0.004 0.004 0.002 0.004 0.949 0.051
PS Adj. 0.000 -0.000 0.003 0.004 -0.000 0.003 0.972 0.028 0.006 0.003 0.004 0.006 0.003 0.968 0.032
Subclass 0.000 0.035 0.004 0.004 0.035 0.005 0.911 0.089 0.007 0.003 0.004 0.007 0.003 0.965 0.035
Matching 0.000 0.035 0.008 0.008 0.035 0.009 0.935 0.065 0.049 0.009 0.010 0.049 0.012 0.926 0.074
Match.-CS 0.000 0.037 0.008 0.008 0.037 0.009 0.936 0.064 0.049 0.010 0.010 0.049 0.012 0.918 0.082
CONV. -0.500 -0.503 0.005 0.005 -0.003 0.005 0.949 1 -0.500 0.004 0.005 -0.000 0.004 0.963 1
PS Adj. -0.500 -0.409 0.004 0.005 0.091 0.012 0.757 1 -0.405 0.004 0.005 0.095 0.013 0.741 1
Subclass -0.500 -0.372 0.004 0.004 0.128 0.020 0.514 1 -0.404 0.004 0.005 0.096 0.013 0.745 1
Matching -0.500 -0.384 0.009 0.009 0.116 0.022 0.777 0.989 -0.382 0.011 0.011 0.118 0.025 0.804 0.953
Match.-CS -0.500 -0.378 0.009 0.009 0.122 0.024 0.749 0.985 -0.379 0.011 0.011 0.121 0.026 0.794 0.953
β=treatment eﬀect, Var(βˆ)= empirical variance, E(V)=average variance,
CONV.=conventional model, PS adj.= Propensity score adjusted into the model, Subclass=subclassification,
Match.-CS= Matching under common support
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Table 3.3: Simulation result of conditional model of 50 confounders
No. confounders=50 Subdistribution model Cause-specific model
Sample size β βˆ V(βˆ) E(V) bias MSE %cov. power βˆ V(βˆ) E(V) bias MSE %cov. power
500 CONV. 0.000 0.003 0.026 0.020 0.003 0.026 0.919 0.081 0.009 0.026 0.020 0.009 0.026 0.922 0.078
PS Adj. 0.000 -0.001 0.013 0.018 -0.001 0.013 0.983 0.017 0.017 0.014 0.018 0.017 0.014 0.979 0.021
Subclass 0.000 -0.163 0.017 0.016 -0.163 0.043 0.732 0.268 0.014 0.014 0.019 0.014 0.014 0.978 0.022
Matching 0.000 -0.166 0.033 0.031 -0.166 0.061 0.835 0.165 -0.011 0.037 0.037 -0.011 0.037 0.947 0.053
Match.-CS 0.000 -0.159 0.033 0.033 -0.159 0.059 0.845 0.155 -0.012 0.039 0.040 -0.012 0.039 0.955 0.045
CONV. -0.500 -0.551 0.029 0.024 -0.051 0.031 0.915 0.928 -0.548 0.031 0.024 -0.048 0.033 0.906 0.923
PS Adj. -0.500 -0.362 0.015 0.021 0.138 0.034 0.875 0.749 -0.361 0.017 0.021 0.139 0.036 0.874 0.726
Subclass -0.500 -0.524 0.019 0.018 -0.024 0.020 0.942 0.971 -0.365 0.017 0.021 0.135 0.036 0.878 0.715
Matching -0.500 -0.532 0.040 0.036 -0.032 0.041 0.947 0.813 -0.407 0.044 0.043 0.093 0.053 0.932 0.498
Match.-CS -0.500 -0.531 0.037 0.038 -0.031 0.038 0.948 0.792 -0.411 0.049 0.046 0.089 0.057 0.923 0.472
1000 CONV. 0.000 -0.008 0.010 0.009 -0.008 0.010 0.934 0.066 0.002 0.010 0.009 0.002 0.010 0.930 0.070
PS Adj. 0.000 -0.005 0.006 0.009 -0.005 0.006 0.981 0.019 0.009 0.006 0.009 0.009 0.006 0.978 0.022
Subclass 0.000 -0.166 0.008 0.008 -0.166 0.035 0.544 0.456 0.007 0.006 0.009 0.007 0.006 0.979 0.021
Matching 0.000 -0.168 0.017 0.017 -0.168 0.045 0.757 0.243 -0.019 0.019 0.020 -0.019 0.020 0.959 0.041
Match.-CS 0.000 -0.172 0.017 0.018 -0.172 0.046 0.762 0.238 -0.014 0.021 0.021 -0.014 0.022 0.958 0.042
CONV. -0.500 -0.527 0.011 0.010 -0.027 0.012 0.935 1 -0.524 0.012 0.010 -0.024 0.013 0.917 1
PS Adj. -0.500 -0.365 0.007 0.010 0.135 0.025 0.756 0.984 -0.367 0.008 0.010 0.133 0.025 0.739 0.987
Subclass -0.500 -0.523 0.009 0.009 -0.023 0.010 0.944 1 -0.369 0.008 0.010 0.131 0.025 0.757 0.987
Matching -0.500 -0.542 0.020 0.019 -0.042 0.021 0.933 0.988 -0.415 0.024 0.024 0.085 0.031 0.908 0.774
Match.-CS -0.500 -0.535 0.021 0.020 -0.035 0.022 0.942 0.976 -0.414 0.025 0.024 0.086 0.033 0.899 0.760
2000 CONV. 0.000 0.001 0.005 0.004 0.001 0.005 0.939 0.061 0.001 0.004 0.004 0.001 0.004 0.941 0.059
PS Adj. 0.000 0.003 0.003 0.004 0.003 0.003 0.980 0.020 0.008 0.003 0.004 0.008 0.003 0.982 0.018
Subclass 0.000 -0.160 0.004 0.004 -0.160 0.030 0.285 0.715 0.006 0.003 0.004 0.006 0.003 0.983 0.017
Matching 0.000 -0.169 0.009 0.009 -0.169 0.038 0.578 0.422 -0.017 0.011 0.011 -0.017 0.011 0.954 0.046
Match.-CS 0.000 -0.159 0.009 0.009 -0.159 0.035 0.584 0.416 -0.018 0.010 0.011 -0.018 0.011 0.952 0.048
CONV. -0.500 -0.511 0.005 0.005 -0.011 0.005 0.936 1 -0.510 0.005 0.005 -0.010 0.005 0.941 1
PS Adj. -0.500 -0.365 0.003 0.005 0.135 0.022 0.506 1 -0.366 0.004 0.005 0.134 0.022 0.493 1
Subclass -0.500 -0.521 0.004 0.004 -0.021 0.005 0.952 1 -0.368 0.004 0.005 0.132 0.021 0.511 1
Matching -0.500 -0.539 0.010 0.010 -0.039 0.012 0.930 0.999 -0.415 0.013 0.012 0.085 0.020 0.868 0.966
Match.-CS -0.500 -0.545 0.009 0.010 -0.045 0.011 0.947 1 -0.413 0.013 0.013 0.087 0.020 0.869 0.969
β=treatment eﬀect, Var(βˆ)= empirical variance, E(V)=average variance,
CONV.=conventional model, PS adj.= Propensity score adjusted into the model, Subclass=subclassification,
Match.-CS= Matching under common support
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Table 3.4: Simulation result of conditional model of 100 confounders
No. confounders=100 Subdistribution model Cause-specific model
Sample size β βˆ V(βˆ) E(V) bias MSE %cov. power βˆ V(βˆ) E(V) bias MSE %cov. power
500 CONV. 0.000 0.003 0.040 0.028 0.003 0.040 0.891 0.109 0.001 0.036 0.030 0.001 0.036 0.926 0.074
PS Adj. 0.000 -0.001 0.012 0.020 -0.001 0.012 0.983 0.017 0.012 0.013 0.021 0.012 0.013 0.988 0.012
Subclass 0.000 -0.216 0.015 0.015 -0.216 0.061 0.578 0.422 0.011 0.013 0.022 0.011 0.013 0.991 0.009
Matching 0.000 -0.223 0.026 0.025 -0.223 0.075 0.696 0.304 -0.020 0.029 0.030 -0.020 0.030 0.955 0.045
Match.-CS 0.000 -0.185 0.027 0.028 -0.185 0.061 0.802 0.198 -0.009 0.033 0.034 -0.009 0.033 0.951 0.049
CONV. -0.500 -0.623 0.046 0.034 -0.123 0.061 0.865 0.906 -0.621 0.046 0.037 -0.121 0.060 0.881 0.885
PS Adj. -0.500 -0.308 0.014 0.023 0.192 0.051 0.800 0.535 -0.335 0.017 0.024 0.165 0.044 0.855 0.590
Subclass -0.500 -0.531 0.017 0.017 -0.031 0.018 0.947 0.989 -0.337 0.017 0.025 0.163 0.044 0.856 0.587
Matching -0.500 -0.544 0.029 0.028 -0.044 0.031 0.937 0.908 -0.374 0.035 0.034 0.126 0.051 0.896 0.540
Match.-CS -0.500 -0.515 0.029 0.032 -0.015 0.029 0.965 0.828 -0.371 0.038 0.039 0.129 0.055 0.889 0.472
1000 CONV. 0.000 0.000 0.012 0.010 0.000 0.012 0.917 0.083 -0.000 0.014 0.010 -0.000 0.014 0.908 0.092
PS Adj. 0.000 -0.001 0.005 0.009 -0.001 0.005 0.987 0.013 0.009 0.007 0.009 0.009 0.007 0.975 0.025
Subclass 0.000 -0.220 0.008 0.007 -0.220 0.056 0.268 0.732 0.006 0.006 0.009 0.006 0.007 0.978 0.022
Matching 0.000 -0.234 0.016 0.014 -0.234 0.070 0.492 0.508 -0.018 0.016 0.017 -0.018 0.016 0.957 0.043
Match.-CS 0.000 -0.218 0.016 0.015 -0.218 0.064 0.553 0.447 -0.013 0.018 0.018 -0.013 0.018 0.937 0.063
CONV. -0.500 -0.546 0.015 0.011 -0.046 0.017 0.886 0.999 -0.543 0.015 0.012 -0.043 0.016 0.907 0.995
PS Adj. -0.500 -0.306 0.006 0.010 0.194 0.044 0.515 0.916 -0.328 0.007 0.011 0.172 0.037 0.635 0.940
Subclass -0.500 -0.523 0.008 0.008 -0.023 0.009 0.942 1 -0.332 0.007 0.011 0.168 0.035 0.653 0.945
Matching -0.500 -0.544 0.016 0.016 -0.044 0.018 0.939 0.990 -0.374 0.017 0.020 0.126 0.033 0.868 0.780
Match.-CS -0.500 -0.542 0.016 0.017 -0.042 0.018 0.933 0.987 -0.365 0.020 0.020 0.135 0.038 0.844 0.731
2000 CONV. 0.000 -0.000 0.005 0.004 -0.000 0.005 0.932 0.068 0.007 0.005 0.005 0.007 0.005 0.924 0.076
PS Adj. 0.000 0.000 0.002 0.004 0.000 0.002 0.989 0.011 0.012 0.003 0.004 0.012 0.003 0.980 0.020
Subclass 0.000 -0.218 0.004 0.004 -0.218 0.051 0.048 0.952 0.010 0.003 0.004 0.010 0.003 0.978 0.022
Matching 0.000 -0.230 0.008 0.008 -0.230 0.061 0.249 0.751 -0.011 0.010 0.009 -0.011 0.010 0.951 0.049
Match.-CS 0.000 -0.238 0.008 0.008 -0.238 0.064 0.236 0.764 -0.014 0.009 0.009 -0.014 0.009 0.956 0.044
CONV. -0.500 -0.525 0.005 0.005 -0.025 0.006 0.923 1 -0.519 0.006 0.005 -0.019 0.007 0.926 1
PS Adj. -0.500 -0.312 0.003 0.005 0.188 0.038 0.151 1 -0.334 0.004 0.005 0.166 0.031 0.319 0.999
Subclass -0.500 -0.524 0.004 0.004 -0.024 0.004 0.942 1 -0.337 0.004 0.005 0.163 0.030 0.326 0.999
Matching -0.500 -0.544 0.008 0.009 -0.044 0.010 0.940 1 -0.376 0.011 0.011 0.124 0.026 0.756 0.959
Match.-CS -0.500 -0.568 0.009 0.009 -0.068 0.013 0.887 1 -0.378 0.011 0.011 0.122 0.026 0.774 0.952
β=treatment eﬀect, Var(βˆ)= empirical variance, E(V)=average variance,
CONV.=conventional model, PS adj.= Propensity score adjusted into the model, Subclass=subclassification,
Match.-CS= Matching under common support
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3.4 Case study results
A total of 71,030 patients were included in the analysis, and 64.5% of them received
statins after discharge. At the end of two years of follow up, the percentage of patients
who had an MI, stroke or HF was 10.2%, 1.8%, 6.1% respectively, the percent who died
was 17.0% (mortality was a competing risk for the CVD events).
We summarized the results from three diﬀerent confounding control methods under
the cause-specific hazard function and the subdistribution hazard function in Table 3.5.
We were not able to apply the PS matching methods due to technical diﬃculties resulting
from the large sample size. The results from both competing risk models suggested that
statins treatment had no eﬀect on the risks of MI, stroke and HF in this cohort. The
reduction in the risk of all-cause mortality was substantial among the treated group.
This may represent healthy user bias, namely, that a healthier or stronger patient is
more likely to get treatment.
In summary, the conditional models suggest that statin use resulted in a large and
statistically significant reduction in mortality, smaller marginally significant eﬀects on
HF and stroke, and a small and not statistically significant eﬀect on MI. These results
can be interpreted as the eﬀect at the individual level conditioning on all the confounders.
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Table 3.5: The estimated treatment eﬀects of statins from conditional models
subdistribution model cause-specific model
βˆ SE p-value βˆ SE p-value
MI Conv. -0.003 0.027 0.900 -0.021 0.027 0.440
PS adj 0.012 0.028 0.660 -0.001 0.028 0.970
subclass -0.011 0.027 0.680 -0.031 0.027 0.260
all-cause Conv. -0.132 0.021 0.000 -0.130 0.021 0.000
mortality PS adj -0.115 0.021 0.000 -0.115 0.021 0.000
subclass -0.163 0.021 0.000 -0.166 0.021 0.000
Stroke Conv. -0.095 0.063 0.130 -0.112 0.063 0.075
PS adj -0.105 0.064 0.100 -0.120 0.064 0.060
subclass -0.112 0.063 0.076 -0.135 0.063 0.032
HF Conv. -0.048 0.035 0.170 -0.066 0.035 0.059
PS adj -0.052 0.036 0.140 -0.064 0.035 0.069
subclass -0.065 0.035 0.065 -0.084 0.035 0.016
β=treatment eﬀect estimator, MI=myocardial infarction,
CONV.=conventional model,
PS adj.= Propensity score adjusted into the model,
Subclass=subclassification,
Match.-CS= Matching under common support
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3.5 Discussion
In this study, we examined the performance of several PS methods in the estimation
of the conditional treatment eﬀect in competing risk analysis. The simulation studies
showed that the covariate adjusted PS method performed the best under the null, and
subclassification performed best under the non-null models, particularly for the subdis-
tribution hazard function with heavy confounding.
Gayat et al (26) and Austin et al (6) examined performance of the PS used in the
standard Cox model via Monte Carlo simulation. The number of confounders of both
studies was small with only 9 variables. They also did not present the extent of overlap
in PS distributions between the treated and untreated groups. Gayat et al. showed that
the matched-robust-adjusted method gave an unbiased estimator, however, this approach
used matched samples, and included confounders into the model. The estimator from
this model was the treatment eﬀects for the treated group. The estimators from the
matched model without adjustment were poor. Austin et al. presented similar results
but also a larger relative bias.
The conventional model was sensitive to sample size. When the sample size was
small and there was a large number of confounding variables, the estimator was biased
and had a large variance. In the real world applications of these methods to studies
using administrative claims data, where the sample size is large and there are many
confounding variables, we recommend that the PS approach be used to reduce the large
number of confounding variables dimensions to one dimension.
The PS matching methods may not be applicable to big datasets. The optimal
matching method needs to create a distance matrix with dimensions of treatment by the
number of untreated patients and use the caliper to find the best matching group (79).
This method requires a lot of time and computing power. In addition, the matching
method has been mostly applied to studies with more untreated patients than treated
patients. However, in studies where treatment is common, the treatment group may be
51
larger than the untreated group and in this case PS matching may result in a reduction
of the sample size.
In conclusion, the PS method is a popular method to balance the diﬀerent base-
line characteristics between treatment groups in observational studies. We have shown
through simulations that the PS methods can be incorporated into competing risk anal-
yses. Recommendations for appropriate PS methods in specific situations have been
provided.
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Chapter 4
Application of Propensity Score Methods for Competing Risks Under
Heterogeneity
4.1 Introduction
Cardiovascular diseases (CVD) are a major leading cause of mortality in the elderly
worldwide (108). High levels of low-density lipoprotein cholesterol (LDL-c) are associated
with an increased risk for CVD events and statins, a class of 3-hydroxy-3-methlglutaryl
coenzyme A reductase inhibitors, are used to lower LDL-c levels, thus helping to prevent
CVD events (100). Clinical trials have demonstrated that statins are highly eﬀective at
lowering LDL-c, which in turn yields great benefit in reducing the number of cardiovas-
cular events (32).
The incidence of CVD rises steeply with age. In 2012, the rate of CVD in men ages
85-94 (7.4%) was more than 20 times that seen in 35-44 year of men (0.3%). Women
followed the same pattern, but 10 years later in life than the men. Adults who were
free from CVD had lifetime cumulative risks of developing CVD of 51.7% (men) and
39.0% (women). The factors related to recurrence of CVD included age, CVD burden
and whether any prevention procedures were performed (109). People surviving an initial
acute myocardial infarction (AMI) are 1.5 to 15 times more likely to suﬀer a repeat AMI
or death, depending on the comorbidities present and their health status (27). This
strong eﬀect
The incidence of CVD rises steeply with age, in 2012, CVD rate increased from 0.3%
at age 35-44 to 7.4% at age 85-94 in men, and schedule 10 years later for women (92).
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The adults who were free from CVD illustrated the life time risks for developing CVD
after 50 year of age with 51.7% in men and 39.2% in women. The factors related to
recurrence of CVD included age, CVD burden and prevention procedure (109). The
people who survived after acute myocardial infarction (AMI) are more likely to suﬀer
and death 1.5 to 15 times more depending on clinical conditions (27). This strong eﬀect
of age on cardiovascular related events led to research on how to treat older patients and
whether the treatment eﬀects of statins seen in clinical trials in fact exist for the older
population.
The eﬀects of statins treatments in the elderly have been investigated, but most results
come from small subgroups, thus are less statistically reliable (28). A meta-analysis of
clinical studies showed the benefit of statins in reducing the risks of all-cause mortality,
MI and stroke in an elderly population, but the most study included the patients who
were free from CVD (87, 1). Also, little evidence is available on the treatment eﬀects
of statins for diﬀerent (combinations of) condition. Due to the potential complexity of
existing comorbidities in the elderly, investigation of treatment eﬀects in this group poses
several challenges including risk of competing events and confounding.
Decreasing rates of coronary heart disease (CHD) during the last two decades come
from improvements in treatment approaches, which Coronary Artery Bypass Grafting
(CABG) or stent or Percutaneous transluminal coronary angioplasty (PTCA) contributed
11% the decrease. Improvements in surgical techniques (including CABG or stent or
PTCA) have improved the survival of MI patients compared with medical therapy alone
(50). The patients who underwent CABG/stent/PTCA possibly lower risks of mortality
and CHD events.
In the previous two chapters, we have shown that propensity score (PS) methods
can be incorporated into competing risk models to evaluate marginal and conditional
treatment eﬀects in non-experimental studies. The approaches have advantages over
conventional models in studies where a large number of confounders exist. However, the
results assume that the treatment eﬀects of statins are homogeneous. In this chapter,
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where we are interested in estimating heterogeneous treatment eﬀects, the PS methods
based on competing risk model are deemed more appropriate.
Heterogeneity treatment eﬀects are the variation in treatment eﬀects among diﬀerent
populations (55). The inclusion criteria of clinical research reduces the heterogeneity
treatment eﬀects and the randomized treatment assignment results in an unbiased esti-
mator. For the non-randomized study, an increase in sample size can reduce sampling
variability but it may not lower heterogeneity (78). A method which can eliminate ma-
jor sources of heterogeneity is important to a non-randomized study. The homogeneity
analyzing by subgroup is the common approach to verify heterogeneity treatment eﬀects.
Age and CABG/stent/PTCA during admission may cause the heterogeneity of statins’s
eﬀects in elderly who AMI. The increasing frailty of old age is likely related to the
risks and the benefits of statins (61). CABG/stent/PTCA procedures are the prefer-
able medical methods to restore the blood flow to the heart by removing or bypassing
the atherosclerosis that causes the blockages in coronary arteries. These procedures can
reduce the risk of overall mortality and recurring MI (53) which may be related to the
interaction of treatment eﬀects between those procedures and statins. The baseline risks
of patients who underwent CABG/stent/PTCA may be diﬀerent from those who did
not have those procedures done; the subgroup analysis resulted in a reduction of those
diﬀerences.
The objective of this study is to investigate the treatment eﬀect of statins in an elderly
population which recently experienced an acute MI. The treatment eﬀect across several
age groups and CABG/stent/PTCA procedures were examined to glean information of
the treatment eﬀects, which hopefully can inform the management and prevention of
cardiovascular events in the elderly population.
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4.2 Method
4.2.1 Source of data and population
We identified a cohort of Medicare beneficiaries who just had a hospitalization stay
for AMI in 2008. AMI was identified from Medicare inpatient claims files using relevant
International Classification of Diseases, Ninth Revision, Clinical Medication (ICD-9-CM)
codes (410.01, 410.11, 410.21, 410.31, 410.41, 410.51, 410.61, 410.71, 410.81, 410.91).
Eligible patients included in the cohort were at least 66 years of age at the index date,
living in the United States and had been continuously enrolled in Medicare Part A, B
and D for at least one year prior. The exposure of interest was statin use after discharge.
4.2.2 Outcome and covariates
These patients were followed up from the 31st day after discharge until the occur-
rence of the first cardiovascular event (recurrent MI, stroke, heart failure) or death. We
created a number of covariates for demographic characteristics and clinical conditions
based on claims occurring in the 12-month baseline period prior to statin initiation.
These covariates were identified a priori based on the literature, substantive knowledge,
and the availability of covariates within the data. The variables included demographic
characteristics age and gender, Charlson comorbidity index (CCI), baseline and current
comorbidities, baseline and current medications, diagnoses and procedures for admission,
and medical procedures during hospital stay (details in Section 1.4).
4.2.3 Statistical analysis
To determine if the treatment eﬀect of statin is heterogeneous across age groups and
patients with or without cardiovascular related procedures during hospital stay for AMI,
we conducted the aforementioned analyses for subgroups. For age, the groups were 66 to
74, 75 to 84, and 85 an older. For the procedure subgroup analysis, patients were grouped
together if they had CABG, stent, or PTCA during the hospital stay. The comparison
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group consisted of patients who did not have any of these procedures.
To estimate the marginal and conditional eﬀect of statin treatment on the risk of
cardiovascular events (recurrent MI, heart failure, and stroke) as a risk in competition
with mortality, we conducted a competing risk analysis with appropriate PS methods
to control for confounding. The competing risk models based on subdistribution hazard
function and cause-specific hazard function were used. For the marginal treatment eﬀect,
we used a crude model, weighted regression with inverse probability treatment weight-
ing (IPTW) (76) and stabilized treatment weighting (STW) (17). For the conditional
treatment eﬀect, we used a conventional model, covariate adjustment using PS and a
subclassification model. The R statistical computing software was used for all analyses.
The R library crr , crrc and crrs were used for subdistribution hazard function based
Fine-Gray model (21). The R library coxph was used to estimate the treatment eﬀect
from cause-specific hazard function based Cox model (103).
4.3 Results
The age distribution of the patients was: 35.1% ages 66-74 years, 40.3% ages 75-84
years, and 24.6% age 85 years and above. Older age groups showed a greater percentage
of patients - the group aged 85 years and older accounted for 40% of total mortality.
Non-statin users ages 66-74 years had twice the risk of dying as did statin users in the
same age group, and 25% of non-statin users aged 85 and older died.
The patients who established hospitalized AMI received CABG/stent/PTCA 42.9%.
75.7% of the patients receiving CABG/stent/PTCA during hospitalization were pre-
scribed statins, but only 56% of patients who did not undergo a revascularization pro-
cedure were prescribed statins. Approximately one-fifth of patients not undergoing
CABG/stent/PTCA who were not prescribed statins died, compared with only 5% of
patients receiving both revascularization and statins. Nearly 14% of patients not under-
going revascularization had heart failure, whether they were prescribed statins or not.
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Table 4.1: Number and percent of observed events
Survived Death MI Stroke HF
Number(%) Number(%) Number(%) Number(%) Number(%)
statins
age 66-74 14609 (73.51) 1545 ( 7.77) 1481 ( 7.45) 447 ( 2.25) 1791 ( 9.01)
age 75-84 9932 (67.25) 1549 (10.49) 1267 ( 8.58 ) 401 ( 2.72) 1619 (10.96)
age > 84 3985 (53.84) 1246 (16.83) 911 (12.31) 225 ( 3.04) 1035 (13.98)
non-Vasc. 12293 (56.36) 3341 (15.32) 2508 (11.50) 616 (2.82) 3055 (14.01)
Vasc. 17561 (79.58) 1152 ( 5.22) 1274 ( 5.77) 499 ( 2.26) 1580 ( 7.16)
Non-statins
age 66-74 5680 (61.83) 1236 (13.45) 864 ( 9.40) 275 ( 2.99) 1132 (12.32)
age 75-84 4638 (57.25) 1347 (16.63) 766 ( 9.45) 266 ( 3.28) 1085 (13.39)
age > 84 2610 (43.61) 1598 (26.70) 689 (11.51) 165 ( 2.76) 923 (15.42)
non-Vasc. 8369 (49.04) 3801 (22.27) 1831 (10.73) 535 ( 3.14) 2529 (14.82)
Vasc. 5083 (71.83) 515 ( 7.28) 563 ( 7.96) 196 ( 2.77) 719 (10.16)
4.3.1 Propensity Score model
A multiple logistic regression model was used to estimate propensity score for each age
group and each procedure group. The distribution of PS for treated and untreated groups
were diﬀerent for age groups and revascularization group (Figure 4.1 and Figure 4.2). The
discrimination of distribution between statins users and non-statins users increased by
age groups. The shape of the density function of statins and non-statin group diﬀered
among patients who underwent CABG/stent/PTCA during admission and patients who
did not undergo those procedures.
The important variables that predicted the probability to be prescribed statins for
all age groups were baseline statins, beta blocker users and admission for CABG or stent
or PTCA. The patients who had CCI for moderate to severe liver disease reduced the
probability of statin in elderly less than 85 years old. Patients ages 75 to 84 years who
had hyperkalemia at baseline were more likely to be prescribed statins, as were patients
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with rhabdomyolysis in the 85+ age group.
The important variables that predicted the probability of receiving statins for the
patients who did not have CABG/stent/PTCA at admission were statin or beta blocker
users at baseline, and the CCI for moderate to severe liver disease. For patients who
received CABG/stent/PTCA, the important variables that predicted the probability of
being prescribed statins were the CCI for diabetes, the CCI for uncomplicated diabetes,
a baseline CCI score greater than 9, ACEI, baseline statins and beta blocker users.
4.3.2 Treatment eﬀects of statins for diﬀerent age groups
The marginal model presented in the previous chapter showed that statins reduced
the risk of mortality and heart failure in the elderly patient who recently experience AMI.
The treatment eﬀect of statins from the conditional model was associated only with a
reduction of mortality hazard. The treatment eﬀect of statins varied by age group -
for patients aged 66 to 74 years, statins were associated with a reduction of the risk of
heart failure, but this was not the case for the other age groups. The treatment eﬀect of
statins with respect to the risk of heart failure was the lowest for those age 85+, whereas
the treatment eﬀect of statins with respect to the risk of mortality was the least in the
younger age groups.
The estimator from marginal model for mortality and heart failure outcome diﬀered in
the conditional model for the 66-74 age group. The weighted model from both subdistri-
bution hazard model and cause-specific model showed a non-significant eﬀect for statins
on reduce the risks of mortality but patients who prescribed statins showed significantly
lower risks of mortality in the the conventional model and subclassification model. In
contrast, the average treatment eﬀects of statins significantly reduced the risk of heart
failure but conditional model showed the opposite results.
Then, the average treatment eﬀects of statins reduced the risk of heart failure in
patients age 66-74 with a recent AMI but this results did not apply at the individual
level. The individual who was prescribed statins has a similar risk of a cardiovascular
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Figure 4.1: Distribution of propensity score of statins users and non-users by age group–
66-74 yrs. (above), 75-84 yrs. (middle), at least 85 (below)
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Figure 4.2: Distribution of propensity score of statins user and non-user by revasucular-
ization status
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event as the individual not prescribed statins and was as likely to be prescribed statins.
In summary, statins showed less of an eﬀect on the risk of CVD, MI, stroke or heart
failure in the older age groups. Healthier older patients may have had a greater chance of
being prescribed statins, thus the statins group showed a lower risk of mortality, especially
for the older patients.
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Table 4.2: Results of treatment eﬀects from the marginal, conditional risks and competing risks models, by age group
age 66-75 yrs. age75-84 yrs. age ≥ 85 yrs.
SH CSH SH CSH SH CSH
βˆ SE p βˆ SE p βˆ SE p βˆ SE p βˆ SE p βˆ SE p
Mortality
Crude -0.537 0.039 0.000 -0.563 0.039 0.000 -0.503 0.029 0.000 -0.528 0.029 0.000 -0.406 0.029 0.000 -0.427 0.029 0.000
Crude-CS -0.536 0.039 0.000 -0.563 0.039 0.000 -0.502 0.029 0.000 -0.528 0.029 0.000 -0.040 0.029 0.000 -0.425 0.029 0.000
IPTW∗ 0.003 0.028 0.909 0.008 0.028 0.786 -0.060 0.021 0.004 -0.060 0.021 0.004 0.058 0.022 0.009 -0.060 0.023 0.008
STW∗ -0.029 0.043 0.505 0.027 0.043 0.526 -0.124 0.029 0.000 -0.126 0.029 0.000 -0.184 0.034 0.000 -0.193 0.027 0.000
Conv. -0.120 0.044 0.006 -0.096 0.044 0.030 -0.140 0.033 0.000 -0.154 0.033 0.000 -0.124 0.034 0.000 -0.118 0.034 0.000
PS-Adj. -0.078 0.045 0.084 -0.070 0.045 0.120 -0.122 0.034 0.000 -0.121 0.034 0.000 -0.115 0.034 0.001 -0.121 0.033 0.000
Subclass. -0.152 0.043 0.000 -0.152 0.044 0.000 -0.173 0.033 0.000 -0.176 0.033 0.000 -0.145 0.033 0.000 -0.155 0.033 0.000
Non-Fetal MI
Crude -0.256 0.046 0.000 -0.302 0.046 0.000 -0.102 0.040 0.010 -0.166 0.040 0.000 0.013 0.041 0.750 -0.062 0.041 0.130
Crude-CS -0.256 0.046 0.000 -0.302 0.046 0.000 -0.103 0.040 0.009 -0.166 0.040 0.000 0.015 0.041 0.710 -0.060 0.041 0.150
IPTW∗ -0.016 0.032 0.616 -0.011 0.032 0.736 0.025 0.027 0.359 0.019 0.027 0.476 0.091 0.029 0.001 0.076 0.029 0.008
STW∗ -0.053 0.047 0.259 -0.051 0.047 0.276 0.009 0.040 0.822 -0.003 0.040 0.941 0.060 0.049 0.222 0.024 0.049 0.624
Conv. -0.057 0.051 0.265 -0.061 0.052 0.240 -0.008 0.045 0.866 -0.033 0.044 0.457 0.050 0.047 0.293 0.031 0.047 0.513
PS-Adj. -0.036 0.052 0.490 -0.036 0.052 0.490 0.010 0.045 0.820 -0.003 0.045 0.950 0.053 0.047 0.260 0.028 0.047 0.550
Subclass. -0.081 0.051 0.110 -0.090 0.051 0.077 -0.010 0.044 0.820 -0.030 0.044 0.500 0.038 0.047 0.430 0.006 0.047 0.890
Stroke
Crude -0.212 0.095 0.026 -0.279 0.095 0.003 -0.105 0.087 0.220 -0.188 0.087 0.030 0.001 0.120 0.990 -0.097 0.120 0.420
Crude-CS -0.212 0.095 0.026 -0.279 0.095 0.003 -0.106 0.087 0.220 -0.188 0.087 0.030 -0.005 0.120 0.970 -0.103 0.120 0.390
IPTW∗ -0.102 0.067 0.129 -0.097 0.067 0.150 -0.079 0.064 0.216 -0.083 0.063 0.191 0.007 0.083 0.936 -0.004 0.084 0.966
STW∗ -0.121 0.092 0.186 -0.122 0.092 0.184 -0.119 0.082 0.144 -0.132 0.082 0.107 0.028 0.144 0.847 -0.014 0.108 0.893
Conv. -0.128 0.106 0.225 -0.136 0.106 0.200 -0.126 0.097 0.194 -0.142 0.097 0.142 -0.048 0.137 0.723 -0.075 0.136 0.582
PS-Adj. -0.138 0.107 0.200 -0.142 0.108 0.190 -0.129 0.098 0.180 -0.144 0.097 0.140 -0.054 0.138 0.700 -0.079 0.137 0.560
Subclass. -0.143 0.106 0.180 -0.158 0.106 0.140 -0.156 0.096 0.110 -0.178 0.096 0.065 -0.044 0.137 0.750 -0.082 0.136 0.550
Heart Failure
Crude -0.175 0.057 0.002 -0.229 0.057 0.000 -0.093 0.048 0.052 -0.164 0.048 0.001 0.025 0.061 0.680 -0.061 0.061 0.310
Crude-CS -0.176 0.057 0.002 -0.230 0.057 0.000 -0.091 0.048 0.056 -0.163 0.048 0.001 0.027 0.061 0.660 -0.583 0.061 0.340
IPTW∗ -0.093 0.036 0.010 -0.086 0.036 0.018 -0.036 0.033 0.276 -0.039 0.033 0.234 -0.087 0.044 0.051 -0.095 0.044 0.032
STW∗ -0.108 0.052 0.039 -0.105 0.052 0.045 -0.066 0.045 0.140 -0.076 0.045 0.089 -0.023 0.075 0.759 -0.057 0.052 0.277
Conv. -0.064 0.063 0.312 -0.070 0.064 0.272 -0.033 0.053 0.534 -0.057 0.053 0.282 -0.075 0.069 0.277 -0.098 0.069 0.156
PS-Adj. -0.059 0.064 0.360 -0.061 0.065 0.350 -0.035 0.054 0.510 -0.048 0.054 0.380 -0.084 0.069 0.220 -0.104 0.069 0.130
Subclass. -0.082 0.063 0.200 -0.092 0.063 0.140 -0.044 0.053 0.410 -0.064 0.053 0.230 -0.079 0.070 0.260 -0.109 0.069 0.120
*SE estimated from bootstrap method, SH=subdistribution model, CSH=cause-specific model
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4.3.3 Treatment eﬀects of statins for patients who had a revascularization
procedure
The eﬀects of statins for patients who underwent CABG/stent/ptca procedures at ad-
mission were diﬀerent from those of patients who did not undergo CABG/stent/PTCA.
The treatment eﬀects of statins of patients with those procedure showed significant re-
ductions in the risks of recurring MI, heart failure and all cause mortality. However,
prescriptions of statins to patients of this group did not significantly reduce the risks of
stroke. The estimator from the cause-specific model were larger than the estimator from
the subdistribution hazard function.
Prescribing statins to non-CABG/stent/ptca patients did not reduce the risks of MI,
stroke and heart failure but it significantly reduced the risks of all-cause mortality. How-
ever, the estimator of marginal model from the subdistribution hazard model showed a
significant increasing the risk of MI for patients from non-CABG/stent/PTCA group.
The results of significant level between marginal and conditional were the same direction
except the estimator of the non-CABG/stent/PTCA group for the risk of MI. The re-
sults from marginal model Fine-Gray model and Cox PH model were diﬀerent when the
outcome was MI in the non-CABG/stent/PTCA group.
In conjunction with CABG/stent/PTCA, prescribing statins improved the eﬀects of
medical treatment for recurrent MI and heart failure, compared with only prescribing
statins. The association of statins with a reduced risk of death was demonstrated in
both groups. These results may have healthy patient bias eﬀects. The Cox PH model
showed larger treatment eﬀects than did the Fine-Gray model.
4.4 Discussion
Statins did not reduce the risks of CVD for those aged 75 years or more but do provide
a reduction in the risk of all-cause mortality. A Canadian observational study of patients
ages 66-85 years with heart failure showed an eﬀect of statins on mortality and stroke,
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Table 4.3: Treatment eﬀects of statins by status of revascularization procedure
CABG/stent/PTCA non-CABG/stent/PTCA
SH CSH SH CSH
βˆ SE p βˆ SE p βˆ SE p βˆ SE p
Mortality
Crude -0.395 0.043 0.000 -0.427 0.043 0.000 -0.338 0.021 0.000 -0.343 0.021 0.000
Crude-CS -0.394 0.043 0.000 -0.425 0.043 0.000 -0.338 0.021 0.000 -0.343 0.021 0.000
IPTW∗ -0.133 0.032 0.000 -0.141 0.032 0.000 -0.060 0.014 0.000 -0.056 0.014 0.000
STW∗ -0.095 0.050 0.060 -0.101 0.050 0.045 -0.175 0.019 0.000 -0.171 0.019 0.000
Conv. -0.186 0.046 0.000 -0.210 0.046 0.000 -0.107 0.023 0.000 -0.099 0.023 0.000
PS-Adj. -0.170 0.047 0.000 -0.181 0.047 0.000 -0.100 0.023 0.000 -0.095 0.023 0.000
Subclass. -0.205 0.046 0.000 -0.222 0.046 0.000 -0.127 0.023 0.000 -0.124 0.023 0.000
Non-Fetal MI
Crude -0.323 0.047 0.000 -0.357 0.047 0.000 0.088 0.028 0.002 0.035 0.028 0.220
Crude-CS -0.322 0.047 0.000 -0.356 0.047 0.000 0.088 0.028 0.002 0.035 0.028 0.220
IPTW∗ -0.093 0.033 0.005 -0.102 0.033 0.002 0.044 0.020 0.030 0.037 0.020 0.063
STW∗ -0.098 0.050 0.048 -0.105 0.050 0.036 0.067 0.027 0.013 0.044 0.027 0.102
Conv. -0.144 0.051 0.005 -0.174 0.051 0.001 0.059 0.032 0.069 0.047 0.032 0.150
PS-Adj. -0.128 0.051 0.013 -0.141 0.051 0.006 0.061 0.032 0.060 0.048 0.032 0.140
Subclass. -0.158 0.050 0.002 -0.175 0.050 0.001 0.060 0.032 0.063 0.042 0.032 0.190
Stroke
Crude -0.161 0.089 0.073 -0.214 0.089 0.017 -0.099 0.075 0.190 -0.158 0.075 0.035
Crude-CS -0.155 0.090 0.084 -0.208 0.090 0.020 -0.099 0.075 0.190 -0.158 0.075 0.035
IPTW∗ -0.060 0.061 0.322 -0.074 0.061 0.224 -0.106 0.053 0.045 -0.111 0.053 0.035
STW∗ -0.081 0.096 0.397 -0.092 0.096 0.338 -0.088 0.065 0.178 -0.111 0.065 0.090
Conv. -0.088 0.097 0.362 -0.115 0.096 0.232 -0.116 0.085 0.174 -0.127 0.085 0.135
PS-Adj. -0.082 0.097 0.400 -0.104 0.097 0.290 -0.125 0.086 0.150 -0.135 0.085 0.110
Subclass. -0.100 0.096 0.300 -0.128 0.096 0.180 -0.129 0.085 0.130 -0.147 0.085 0.084
Heart Failure
Crude -0.251 0.053 0.000 -0.290 0.053 0.000 0.053 0.039 0.180 -0.002 0.039 0.950
Crude-CS -0.251 0.053 0.000 -0.290 0.053 0.000 0.054 0.039 0.170 -0.002 0.039 0.970
IPTW∗ -0.132 0.036 0.000 -0.141 0.036 0.000 -0.044 0.028 0.114 -0.047 0.028 0.092
STW∗ -0.117 0.057 0.039 -0.123 0.057 0.030 0.017 0.034 0.609 -0.004 0.033 0.904
Conv. -0.125 0.057 0.028 -0.155 0.057 0.006 -0.023 0.045 0.610 -0.033 0.045 0.457
PS-Adj. -0.123 0.058 0.033 -0.138 0.058 0.017 -0.023 0.045 0.600 -0.033 0.045 0.460
Subclass. -0.151 0.057 0.008 -0.171 0.057 0.003 -0.037 0.045 0.400 -0.053 0.044 0.240
*SE estimated from bootstrap method, SH=subdistribution model, CSH=cause-specific model
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but not for MI (12). Younger age groups (less than 85 years old) showed a greater eﬀect
of statins than did those over 84 years of age. A meta-analysis in patients (maximum
age 82) who did not have cardiovascular disease but had cardiovascular risk factors found
that statins reduce the risk of death, major coronary events and major cerebrovascular
events (12).
Statins were associated with a reduced risk of mortality in all age groups but older
elderly showed a greater reduction in mortality risk than did the younger elderly. The
eﬀect of statins on mortality has been documented by many studies but with contradic-
tory results. Observational studies of patients with heart failure found that statins can
reduce risks of mortality (69, 24, 45, 22). In contrast, the meta-analysis of randomized
controlled trials of subjects without CVD at baseline did not show the same eﬀects of
statins on all cause mortality (74). A long-term follow-up study of CHD patients or high
risks in CHD patients found that statins significantly reduced mortality from cardiovas-
cular disease but it did not reduce non-cardiovascular mortality (60). The diﬀerence in
medical history of patients aﬀected the treatment eﬀects of statins on mortality.
Statins are associated with a reduced risk of death in the oldest age group, but show
non-significant treatment eﬀects on the risk of MI, stroke and heart failure. Moreover,
the treatment eﬀects are reversed for MI. For the oldest age group, statins appear to
operate using a diﬀerent prediction model. The oldest elderly were vulnerable and frail.
Optimal medication use in the elderly must take into account both the benefit and risks,
especially for patients with a short life expectancy (44). In addition, the elderly often have
several comorbidities and polymedication, therefore the standard guidelines may not be
suitable for all elderly patient (93). Although statins are associated with the prevention
of CVD in the elderly, they also may cause myopathy (41). Lee and colleagues (58) found
that intermediate acute coronary syndrome patients aged 81+ years were less likely to
be prescribed secondary prevention medication such as ARB, ACE or statins. Whether
statins are prescribed depends on the patient’s medical condition and the decision of their
physician. However, statins are recommended for the elderly, particularly the healthy
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elderly with more years of life left who may benefit more from statin’ eﬀects (28).
Although the eﬀects of statins in patients who underwent CABG/stent/PTCA pro-
cedure have been shown, adherence to statins after a procedure was low compared to
revascularization procedures alone (49). Prescribing statins tend to be performed more
in younger age groups (almost 80% of those 75 years of age or older are not routinely
treated), demonstrating a healthy bias eﬀect.
The heterogeneity of statins treatment eﬀects can be seen in this study, since age and
CABG/stent/PTCA procedures modify the eﬀect of statins. Overall treatment eﬀects
under heterogeneity need the weighted methods. The standardized method including
IPTW allows the summary estimation of treatment eﬀects in certain populations (97).
Limitation
Including both new and recurring MI into the cohort causes the diﬀerent probabilities
of recurrence of MI (68). Clinical data, such as the size and the area of infarction, were not
included in the model. Underlying cause of death cannot be reliably linked to CHD. The
dataset constructed for this analysis did not include the initiation date nor the length of
use of statins. Discontinuing use of statins after discharge showed strong harmful eﬀects
in patients, which were not seen in patients not prescribed statins (20).
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Chapter 5
Conclusion
This study investigated the eﬃciency of estimators when propensity score methods
were used to reduce or eliminate the eﬀect of confounding in competing risks survival
analysis. We investigated the treatment eﬀects estimator from both marginal and con-
ditional models. The PS methods for estimating marginal treatment eﬀects included a
crude model and weighted model. The subclassification model, matching and PS were
included in a multivariate model; the matching model used the PS methods to estimate
conditional treatment eﬀects. This study also applied a conventional model which in-
cluded all confounding into the model to compare eﬃciency of the conventional method to
PS methods. The competing risks models of this study included a cause-specific hazard
model and a subdistribution hazard model.
The PS methods showed the good performance for estimate marginal treatment eﬀect
when applied to competing risks analysis. The weighted model showed a small amount
of bias in the MSE, and a high percent of coverage. However, we found the inflated
variance of estimator in the scenario of low occurrence of the interesting event and the
heavy confounder. The bootstrapping methods applied to obtain the variance estimator
appropriately take advantage of the estimation of variance for weighed models. A future
research topic for the estimator from the marginal model will be the investigation of the
behavior of the inflated variance from the weighted model in diﬀerent scenarios. Another
topic for future research is the development of a better method to estimate the variance
of the weighted model.
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The estimator from PS methods also showed the good performance for conditional
model especially given the large amount of confounding present. PS adjusted into multi-
variate competing risk model showed good performance for null model, which illustrated
high percent coverage, small bias and MSE for all scenarios. For alternative model, when
the PS model included heavy confounders, the subclassification model showed the small-
est MSE of subdistribution hazard model. However, subclassification showed a larger bias
compared to conventional model. For the cause-specific hazard model, the conventional
model showed a small bias, small MSE and high percent coverage. Under Monte Carlo
simulation, the confounder variables were independent, but may have been correlated.
The performance of PS methods under certain level of correlation between confounder
variables should to be investigated in the future.
We presented the case study of applying PS methods to estimate treatment eﬀects
with a competing risks model. The Medicare claims data included a cohort of patients
who were recently hospitalized for AMI in 2008. The treatment eﬀect of statins in this
population was investigated. The outcomes of interest were MI, stroke, heart failure
and all cause mortality. We believe that the estimators from weighted model showed
the best marginal estimator. The estimators from PS, added to the multivariate model,
produced a good estimator for null model, while the good estimators for the alternative
model of subdistribution hazard model and the cause-specific model were the subclassifi-
cation model and the conventional model respectively. The marginal estimator from the
weighted model demonstrated the benefit of statins in reducing hazard of heart failure
and all cause mortality in this population. However, the conditional model showed the
eﬀect of statins of all-cause mortality.
The dataset for this hospitalized elderly contains the variation contributed by indi-
viduals and their medical condition. The heterogeneity treatment eﬀects may show in
the results for the diﬀerent age and medical procedure group. The heterogeneity treat-
ment eﬀect represents the interaction between treatment eﬀects and individual patient
characteristics. However, the PS methods cannot include the interaction between eﬀect
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and confounding factors needed to investigate heterogeneity of treatment. The subgroup
analysis is the considering tool to estimate treatment eﬀect when the heterogeneity treat-
ment eﬀect possibly present.
The results showed a heterogeneity of treatment eﬀects by age group and procedure
of CABG/stent/PTCA. The younger elderly showed a greater eﬀect of statins on the
secondary prevention of heart failure than was seen in older elderly. The patients who
underwent CABG/stent/PTCA showed more of an eﬀect of statins on MI and heart
failure than those patients who were only prescribed statins. However, the results of
heterogeneity treatment eﬀect may be related to the healthy bias eﬀect. The younger
elderly and the patients who had CABG/stent/PTCA were stronger and healthier than
other groups.
The appropriate PS model showed good performance in controlling confounder in
competing risks survival analysis. PS methods produced good estimators for both sub-
distribution and cause-specific hazard models. When the heterogeneity treatment eﬀects
may be present, subgroup analysis should be performed to investigate the treatment
eﬀects for each subgroup.
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APPENDIX: Propensity Score model
Table 5.1: Propensity score model
Variables Estimation SE P-value
intercept -1.094 0.092 0.000
Age ×comobidity 0.027 0.016 0.099
gender 0.013 0.020 0.516
Age 65-74 yrs.
Age 75-84 yrs. -0.045 0.022 0.045
Age 85 yrs. and more -0.118 0.029 0.000
White
Black 0.042 0.034 0.207
Asian 0.072 0.056 0.201
Hispanic 0.205 0.071 0.004
Other race 0.216 0.071 0.002
Income less than $30,001
Income $30,001-$60,000 0.105 0.073 0.141
Income $60,001-$100,000 0.168 0.074 0.024
Income $100,001-$150,000 0.201 0.083 0.015
Income more than $150,000 0.211 0.106 0.046
Charlson Comorbidity index
Acute Myocaridal Infarction 0.108 0.045 0.016
Cerebrovascular Disease -0.012 0.031 0.687
Congentive heart failure 0.011 0.031 0.758
Periphral vascular disease 0.032 0.030 0.291
Diabetes -0.036 0.111 0.747
Renal disease 0.147 0.039 0.000
Chronic Obstructive Pulmonary disease 0.095 0.036 0.009
Peptic Ulcer disease 0.064 0.072 0.371
Cancer -0.007 0.039 0.860
Dementia 0.003 0.055 0.956
Connective Tissue disease Rheumatic disease 0.008 0.051 0.877
Mild liver disease -0.160 0.071 0.024
Moderate to severe liver disease -0.578 0.213 0.007
Paralysis 0.079 0.097 0.414
Metastatic Carsinoma -0.024 0.103 0.813
AIDS/HIV -0.033 0.374 0.931
Diabetes without complication 0.000 0.109 0.999
Diabetes with complications 0.036 0.042 0.384
Baseline disease
Stent -0.002 0.162 0.510
PTCA -0.101 0.112 0.365
Unstable angina 0.034 4.020 0.391
Ischemic heart disease -0.334 0.023 0.000
Atrial fibrillation -0.065 0.030 0.031
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Variables Estimation SE P-value
Hypertension 0.006 0.025 0.794
Hyperlipidemia -0.221 0.022 0.000
End-stage renal disease 0.027 0.088 0.760
Osteroporosis 0.011 0.036 0.756
Asthma 0.098 0.042 0.019
Angiodedma&hyperkalemia 0.084 0.198 0.672
Hypotension -0.015 0.043 0.730
Sinus bradycardia&heart block -0.012 0.026 0.647
Rhabdomyolysis -0.234 0.138 0.090
Hyperkalemia 0.021 0.204 0.917
Baseline CCI=0 -0.080 0.035 0.023
Baseline CCI=1-2 -0.171 0.038 0.000
Baseline CCI=3-5 -0.233 0.063 0.000
Baseline CCI=6-8 -0.305 0.100 0.002
Baseline CCI more than 9 -0.387 0.146 0.008
Baseline medication
Baseline Beta blocker -0.230 0.020 0.000
Baseline ACEI/ARB -0.157 0.021 0.000
Baseline STATINS 1.659 0.022 0.000
BaselineCoronary Artery bypass grafting 0.076 0.116 0.510
Baseline STENT/PTCA -0.127 0.190 0.503
Admission procedure/diagnosis
Subendocardial infarction -0.104 0.022 0.000
Congestive heart failure -0.094 0.021 0.000
Cardiogenic shock 0.097 0.064 0.129
Acute renal failure 0.029 0.029 0.314
Hypotension 0.047 0.041 0.248
Cardiac dysrhythmias -0.062 0.020 0.002
Cardiac catheterization 0.118 0.036 0.001
CABG 0.682 0.043 0.000
PTCA -0.142 0.518 0.784
STENT/PTCA 0.655 0.518 0.206
Angiocardiography 0.162 0.035 0.000
Thromblytics and patelet inhibitors -0.029 0.121 0.811
Platelet inhibitors 0.177 0.046 0.000
Number of days in ICU=0
Number of days in ICU=1-3 0.044 0.022 0.042
Number of days in ICU=4-10 0.015 0.027 0.579
Number of days in ICU ¿10 -0.016 0.064 0.807
Number of coronary care unit=0
Number of coronary care unit= 1-3 0.129 0.024 0.000
Number of coronary care unit= 4-10 0.113 0.030 0.000
Number of coronary care unit ¿10 0.057 0.077 0.457
Total number of days in hospital
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Variables Estimation SE P-value
1 day in hospital -0.091 0.053 0.087
2-5 days in hospital 0.048 0.032 0.130
6-10 days in hospital -0.045 0.031 0.141
More than 10 days in hospital -0.102 0.049 0.039
Acute respiratory failure/ -0.061 0.032 0.056
Mechventilation in AMI admission
Septic shock in AMI admission -0.161 0.129 0.212
Physician visit during follow-up 0.143 0.023 0.000
Cardiologist visit during follow-up 0.120 0.021 0.000
Revascularization procedure during follow-up 0.127 0.037 0.001
Number of hospital admission in baseline -0.027 0.018 0.143
Number of days in hospital in baseline 0.001 0.001 0.656
Indicator for hospital admission in baseline 0.044 0.033 0.184
Number of admission to short-term -0.004 0.029 0.893
Acute care hospital during follow up
Number of days to short term -0.009 0.004 0.033
Acute care hospital during follow up
Medicare DOUGNUT -0.012 0.030 0.691
Low comorbidity level
Moderate comorbidity level -0.122 0.046 0.008
High comorbidity level -0.095 0.076 0.211
Current Beta blockers 0.987 0.022 0.000
Current ACEI/ARB 0.319 0.081 0.000
CurrentACEI 0.342 0.081 0.000
CurrentARB 0.186 0.076 0.014
Current comorbidity
Valvular disease or rheumatic heart disease -0.010 0.023 0.667
Other neurological disorders -0.030 0.029 0.304
Obesity -0.013 0.041 0.746
Coagulation deficiency -0.028 0.041 0.486
Weight loss -0.021 0.036 0.560
Fluid/electrolyte disorder -0.054 0.025 0.033
Substance abuse -0.025 0.072 0.731
Blood loss&deficiency anemia -0.087 0.022 0.000
Hypothyroidism -0.041 0.022 0.063
Pulmonary Circ. Disorders -0.034 0.039 0.379
Osteoarthritis -0.026 0.020 0.210
GI bleed -0.031 0.037 0.396
Parkinson’s disease -0.045 0.071 0.522
Weakness 0.041 0.046 0.371
Vertigo 0.010 0.026 0.708
Fall/diﬃculty walking 0.036 0.028 0.193
Bladder dysfunction 0.006 0.030 0.848
Decubitus -0.032 0.039 0.412
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Variables Estimation SE P-value
Use of Oxygen -0.031 0.033 0.348
Use of hospital bed 0.055 0.057 0.336
Use of ambulance 0.019 0.023 0.398
Nail care 0.025 0.027 0.345
Use of other assistive devices -0.011 0.045 0.815
Use of screening 0.029 0.023 0.196
Use of wheelchair 0.053 0.042 0.207
Use of rehabilitation -0.009 0.026 0.721
Figure 5.1: Distribution of the propensity score of statins users and non-users by revas-
cularization procedure group
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Table 5.2: Propensity score model by age groups
age 66-74 yrs. age 75-84 yrs. age 85 and older
Variables Estimation SE P-value Estimation SE P-value Estimation SE P-value
Intercept -0.490 0.479 0.307 -0.901 0.427 0.035 -0.029 0.501 0.954
Gender 0.000 0.033 0.999 0.024 0.031 0.430 -0.002 0.041 0.969
Age -0.005 0.006 0.396 -0.323 0.005 0.522 -0.015 0.005 0.003
White
Black 0.083 0.055 0.132 0.004 0.054 0.939 0.035 0.071 0.620
Asian -0.044 0.112 0.693 0.111 0.082 0.179 0.092 0.106 0.386
Hispanic 0.066 0.132 0.616 0.244 0.109 0.025 0.286 0.134 0.032
Other race 0.133 0.112 0.234 0.285 0.118 0.016 0.280 0.149 0.060
Income less than $30,001
Income $30,001-$60,000 0.151 0.120 0.211 0.103 0.118 0.382 0.058 0.149 0.696
Income $60,001-$100,000 0.186 0.123 0.131 0.189 0.120 0.113 0.112 0.151 0.458
Income $100,001-$150,000 0.137 0.142 0.337 0.231 0.133 0.082 0.203 0.164 0.215
Income more than $150,000 0.088 0.198 0.657 0.323 0.169 0.056 0.166 0.198 0.402
Charlson Comorbidity index
Acute Myocaridal Infarction 0.170 0.079 0.031 0.070 0.072 0.326 0.029 0.087 0.737
Cerebrovascular Disease 0.042 0.056 0.453 -0.036 0.047 0.437 -0.051 0.062 0.404
Congentive heart failure 0.005 0.066 0.943 0.066 0.058 0.257 -0.073 0.074 0.318
Periphral vascular disease -0.012 0.054 0.828 0.028 0.047 0.548 0.084 0.061 0.166
Diabetes 0.101 0.190 0.596 -0.385 0.176 0.029 0.288 0.215 0.181
Renal disease 0.188 0.070 0.007 0.094 0.061 0.121 0.155 0.078 0.047
Chronic Obstructive Pulmonary disease 0.116 0.063 0.065 0.120 0.056 0.032 0.005 0.077 0.944
Peptic Ulcer disease -0.116 0.128 0.363 0.184 0.111 0.099 0.086 0.142 0.546
Cancer -0.052 0.070 0.458 0.003 0.059 0.964 0.004 0.081 0.965
Dementia -0.024 0.149 0.869 0.120 0.088 0.170 -0.052 0.088 0.550
Connective Tissue disease Rheumatic disease -0.022 0.087 0.800 -0.070 0.077 0.363 0.194 0.109 0.076
Mild liver disease -0.167 0.108 0.122 -0.142 0.114 0.211 -0.251 0.171 0.143
Moderate to severe liver disease -0.692 0.319 0.030 -0.617 0.332 0.063 -0.271 0.593 0.647
Paralysis 0.197 0.162 0.234 0.038 0.154 0.805 -0.199 0.203 0.325
Metastatic Carsinoma 0.199 0.173 0.250 -0.121 0.156 0.439 -0.247 0.232 0.287
AIDS/HIV 0.049 0.421 0.908 -0.211 0.884 0.812
Diabetes without complication -0.142 0.187 0.449 0.364 0.174 0.036 -0.337 0.212 0.112
Diabetes with complications -0.028 0.070 0.686 0.135 0.065 0.038 -0.046 0.091 0.611
Baseline disease
BaselineCoronary Artery bypass grafting 0.185 0.161 0.251 0.072 0.179 0.688 0.006 0.519 0.990
Stent 0.022 0.263 0.932 0.002 0.236 0.993 0.060 0.421 0.888
PTCA -0.006 0.160 0.970 -0.213 0.176 0.227 -0.171 0.349 0.623
Unstable angina -0.039 0.067 0.557 0.142 0.063 0.025 -0.052 0.085 0.539
Ischemic heart disease -0.370 0.041 0.000 -0.380 0.036 0.000 -0.212 0.044 0.000
Atrial fibrillation -0.014 0.062 0.821 -0.090 0.046 0.054 -0.056 0.054 0.297
Hypertension -0.054 0.043 0.209 0.047 0.039 0.228 0.087 0.048 0.069
Hyperlipidemia -0.313 0.040 0.000 -0.194 0.035 0.000 -0.168 0.045 0.000
End-stage renal disease 0.007 0.135 0.960 0.003 0.135 0.980 0.138 0.222 0.533
Osteroporosis -0.031 0.077 0.683 0.054 0.056 0.328 -0.003 0.060 0.959
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age 66-74 yrs. age 75-84 yrs. age 85 and older
Variables Estimation SE P-value Estimation SE P-value Estimation SE P-value
Asthma 0.134 0.069 0.052 0.136 0.066 0.038 0.003 0.090 0.976
Angiodedma&hyperkalemia 0.314 0.336 0.351 -0.270 0.303 0.373 0.300 0.426 0.481
Hypotension -0.017 0.078 0.823 0.083 0.067 0.216 -0.155 0.081 0.056
Sinus bradycardia&heart block -0.082 0.051 0.107 0.041 0.041 0.316 -0.040 0.048 0.400
Rhabdomyolysis -0.081 0.255 0.751 -0.155 0.228 0.496 -0.497 0.246 0.043
Hyperkalemia -0.273 0.349 0.434 0.503 0.313 0.108 -0.313 0.437 0.474
Baseline CCI=0 -0.079 0.060 0.188 -0.055 0.056 0.327 -0.059 0.068 0.387
Baseline CCI=1-2 -0.247 0.066 0.000 -0.111 0.059 0.061 -0.137 0.076 0.070
Baseline CCI=3-5 -0.265 0.109 0.016 -0.201 0.097 0.038 -0.202 0.129 0.119
Baseline CCI=6-8 -0.337 0.174 0.053 -0.298 0.154 0.054 -0.233 0.209 0.265
Baseline CCI more than 9 -0.412 0.251 0.101 -0.408 0.225 0.070 -0.265 0.311 0.393
Baseline medication
Baseline Beta blocker -0.268 0.036 0.000 -0.240 0.032 0.000 -0.157 0.039 0.000
Baseline ACEI/ARB -0.119 0.037 0.001 -0.197 0.032 0.000 -0.119 0.040 0.003
Baseline STATINS 1.483 0.037 0.000 1.652 0.034 0.000 1.901 0.044 0.000
Baseline STENT/PTCA -0.218 0.298 0.464 -0.029 0.284 0.919 0.032 0.530 0.952
Admission procedure/diagnosis
Subendocardial infarction -0.167 0.037 0.000 -0.057 0.035 0.100 -0.100 0.045 0.025
Congestive heart failure 0.010 0.038 0.804 -0.100 0.032 0.002 -0.167 0.038 0.000
Cardiogenic shock 0.002 0.096 0.985 0.122 0.102 0.232 0.250 0.158 0.114
Acute renal failure 0.003 0.052 0.954 0.067 0.044 0.132 0.015 0.055 0.790
Hypotension 0.045 0.072 0.534 -0.016 0.064 0.800 0.162 0.082 0.047
Cardiac dysrhythmias -0.059 0.037 0.113 -0.050 0.032 0.118 -0.080 0.039 0.043
Cardiac catheterization 0.181 0.056 0.001 0.021 0.055 0.704 0.127 0.095 0.181
CABG 0.674 0.064 0.000 0.693 0.067 0.000 0.611 0.160 0.000
PTCA -0.153 0.830 0.854 -0.214 0.670 0.749 -8.110 119.468 0.946
Angiocardiography 0.036 0.054 0.503 0.223 0.053 0.000 0.247 0.094 0.009
Thromblytics and patelet inhibitors 0.078 0.189 0.680 -0.180 0.184 0.327 0.134 0.311 0.665
Platelet inhibitors 0.040 0.068 0.551 0.243 0.072 0.001 0.443 0.134 0.001
Number of days in ICU=0
Number of days in ICU=1-3 -0.028 0.037 0.461 0.070 0.034 0.040 0.081 0.043 0.061
Number of days in ICU=4-10 -0.032 0.049 0.520 0.006 0.042 0.880 0.053 0.052 0.038
Number of days in ICU ¿10 0.017 0.107 0.875 -0.021 0.096 0.825 -0.151 0.151 0.317
Number of coronary care unit=0
Number of coronary care unit= 1-3 0.094 0.040 0.018 0.123 0.038 0.001 0.168 0.050 0.001
Number of coronary care unit= 4-10 0.018 0.053 0.734 0.175 0.046 0.000 0.098 0.059 0.096
Number of coronary care unit ¿10 -0.044 0.125 0.728 0.070 0.115 0.543 0.184 0.188 0.329
STENT/PTCA 0.634 0.830 0.445 0.723 0.670 0.280
Total number of days in hospital
1 day in hospital -0.072 0.089 0.421 -0.083 0.085 0.329 -0.139 0.111 0.210
2-5 days in hospital 0.027 0.060 0.654 0.029 0.051 0.561 0.106 0.058 0.069
6-10 days in hospital -0.094 0.057 0.097 -0.031 0.049 0.529 -0.022 0.057 0.699
More than 10 days in hospital -0.203 0.089 0.022 -0.057 0.077 0.460 -0.096 0.099 0.334
Acute respiratory failure/
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age 66-74 yrs. age 75-84 yrs. age 85 and older
Variables Estimation SE P-value Estimation SE P-value Estimation SE P-value
Mechventilation in AMI admission -0.011 0.052 0.836 -0.116 0.049 0.018 -0.097 0.070 0.164
Septic shock in AMI admission 0.170 0.214 0.429 -0.356 0.193 0.064 -0.506 0.324 0.118
Physician visit during follow-up 0.191 0.042 0.000 0.123 0.038 0.001 0.119 0.044 0.006
Cardiologist visit during follow-up 0.091 0.036 0.012 0.129 0.033 0.000 0.127 0.044 0.004
Revascularization procudure during follow-up 0.055 0.056 0.325 0.135 0.058 0.020 0.264 0.099 0.007
Number of hospital admission in baseline -0.024 0.031 0.447 -0.043 0.028 0.124 -0.011 0.040 0.779
Number of days in hospital in baseline 0.001 0.003 0.765 0.004 0.002 0.064 -0.004 0.003 0.148
Indicator for hospital admission in baseline 0.116 0.058 0.045 0.007 0.052 0.897 0.035 0.070 0.623
Number of admission to short-term
acute care hospital during follow up -0.037 0.051 0.471 -0.019 0.045 0.676 0.048 0.058 0.412
Number of days to short term acute
care hospital during follow up -0.003 0.008 0.747 -0.012 0.007 0.080 -0.014 0.009 0.099
DOUGNUT -0.029 0.051 0.572 -0.002 0.047 0.961 0.002 0.063 0.976
Low comorbidity level
Moderate comorbidity level -0.067 0.060 0.265 -0.047 0.052 0.361 -0.078 0.062 0.211
High comorbidity level -0.047 0.072 0.515 -0.026 0.062 0.672 0.133 0.081 0.100
Current Beta blockers 1.113 0.037 0.000 0.921 0.034 0.000 0.952 0.043 0.000
Current ACEI/ARB 0.324 0.133 0.015 0.291 0.135 0.031 0.389 0.163 0.017
CurrentACEI 0.312 0.128 0.015 0.436 0.131 0.001 0.210 0.158 0.185
CurrentARB 0.199 0.121 0.102 0.284 0.127 0.025 0.010 0.153 0.947
Current comorbidity
Valvular disease or rheumatic heart disease 0.028 0.043 0.510 -0.050 0.036 0.160 -0.008 0.043 0.853
Other neurological disorders -0.016 0.056 0.769 -0.025 0.045 0.576 -0.043 0.053 0.414
Obesity 0.064 0.057 0.259 -0.106 0.066 0.111 -0.055 0.134 0.683
Coagulation deficiency -0.055 0.075 0.468 -0.015 0.062 0.810 -0.043 0.079 0.587
Weight loss -0.023 0.072 0.755 -0.073 0.056 0.191 0.021 0.065 0.744
Fluid/electrolyte disorder -0.113 0.047 0.016 -0.047 0.040 0.233 -0.002 0.048 0.975
Substance abuse -0.018 0.099 0.855 -0.127 0.124 0.307 -0.093 0.213 0.661
Blood loss&deficiency anemia -0.065 0.042 0.122 -0.077 0.035 0.027 -0.116 0.041 0.005
Hypothyroidism -0.051 0.042 0.221 0.011 0.035 0.751 -0.109 0.041 0.008
Pulmonary Circ. Disorders -0.123 0.071 0.082 -0.047 0.060 0.439 0.056 0.074 0.444
Osteoarthritis -0.069 0.037 0.062 0.004 0.032 0.895 -0.019 0.039 0.627
GI bleed 0.008 0.069 0.912 -0.086 0.056 0.124 0.004 0.070 0.954
Use of screening 0.050 0.041 0.227 -0.024 0.037 0.511 0.044 0.042 0.301
Use of wheelchair -0.028 0.082 0.733 0.049 0.069 0.480 0.121 0.072 0.090
Parkinson’s disease -0.094 0.150 0.529 -0.046 0.105 0.662 -0.052 0.130 0.692
Use of rehabilitation -0.072 0.047 0.125 0.075 0.041 0.067 -0.072 0.051 0.162
Weakness 0.200 0.095 0.035 -0.020 0.072 0.785 0.027 0.080 0.737
Vertigo -0.078 0.048 0.103 0.045 0.040 0.259 0.035 0.048 0.464
Fall/diﬃculty walking 0.082 0.055 0.135 0.008 0.043 0.857 0.047 0.048 0.332
Bladder dysfunction -0.040 0.059 0.501 -0.010 0.046 0.833 0.075 0.056 0.178
Decubitus 0.010 0.074 0.897 -0.053 0.062 0.400 -0.031 0.070 0.659
Use of Oxygen 0.013 0.057 0.815 -0.053 0.051 0.298 -0.077 0.068 0.256
Use of hospital bed 0.126 0.111 0.259 0.146 0.093 0.114 -0.052 0.098 0.597
Use of ambulance 0.090 0.041 0.030 -0.027 0.035 0.444 -0.015 0.043 0.723
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age 66-74 yrs. age 75-84 yrs. age 85 and older
Variables Estimation SE P-value Estimation SE P-value Estimation SE P-value
Nail care 0.035 0.057 0.545 -0.015 0.042 0.714 0.052 0.046 0.255
Use of other assistive devices -0.014 0.090 0.878 -0.128 0.071 0.051 0.125 0.081 0.121
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Table 5.3: Propensity score model by revascularization procedure group
CABG/stent/PTCA No CABG/stent/PTCA
Variables Estimator SE p-value Estimator SE p-value
Intercept 0.139 0.205 0.498 -1.368 0.116 0.000
Gender -0.043 0.032 0.170 0.034 0.026 0.185
Age 66-74 yrs.
Age 75-84 yrs. -0.047 0.032 0.138 -0.017 0.030 0.556
Age 85+ yrs. -0.038 0.049 0.435 -0.052 0.034 0.119
White
Black -0.037 0.062 0.555 0.100 0.041 0.013
Asian 0.086 0.098 0.383 0.091 0.069 0.191
Hispanic 0.322 0.130 0.013 0.169 0.086 0.051
Other race 0.362 0.129 0.005 0.160 0.087 0.066
Income less than $30,001
Income $30,001-$60,000 0.007 0.125 0.952 0.168 0.092 0.068
Income $60,001-$100,000 0.078 0.127 0.538 0.229 0.094 0.014
Income $100,001-$150,000 0.094 0.141 0.503 0.269 0.104 0.010
Income more than $150,000 0.237 0.176 0.177 0.199 0.137 0.145
Charlson Comorbidity index
Acute Myocaridal Infarction 0.104 0.087 0.234 0.059 0.053 0.262
Cerebrovascular Disease -0.031 0.056 0.573 -0.011 0.037 0.777
Congentive heart failure 0.049 0.071 0.485 -0.043 0.044 0.329
Periphral vascular disease 0.053 0.055 0.340 0.017 0.037 0.648
Diabetes -0.619 0.181 0.001 0.268 0.138 0.052
Renal disease 0.123 0.075 0.101 0.131 0.047 0.005
Chronic Obstructive Pulmonary disease 0.178 0.066 0.007 0.055 0.044 0.219
Peptic Ulcer disease 0.156 0.137 0.253 0.007 0.086 0.939
Cancer 0.077 0.070 0.270 -0.061 0.049 0.212
Dementia 0.207 0.140 0.139 -0.036 0.062 0.563
Connective Tissue disease Rheumatic disease 0.040 0.086 0.638 -0.034 0.065 0.602
Mild liver disease -0.213 0.121 0.079 -0.132 0.089 0.135
Moderate to severe liver disease -0.272 0.461 0.556 -0.679 0.247 0.006
Paralysis 0.021 0.206 0.919 0.071 0.111 0.523
Metastatic Carsinoma 0.421 0.207 0.043 -0.149 0.122 0.222
AIDS/HIV 0.354 0.651 0.587 -0.213 0.462 0.644
Diabetes without complication 0.570 0.179 0.001 -0.301 0.136 0.027
Diabetes with complications 0.080 0.076 0.293 0.001 0.051 0.987
Baseline disease
BaselineCoronary Artery bypass grafting -0.055 0.176 0.756 0.232 0.154 0.133
Stent -0.025 0.228 0.914 0.069 0.226 0.760
PTCA -0.214 0.136 0.115 0.206 0.212 0.332
Unstable angina 0.065 0.066 0.322 -0.006 0.051 0.903
Ischemic heart disease -0.495 0.038 0.000 -0.234 0.029 0.000
Atrial fibrillation 0.086 0.059 0.144 -0.108 0.036 0.003
Hypertension 0.049 0.039 0.210 -0.003 0.032 0.932
Hyperlipidemia -0.425 0.037 0.000 -0.111 0.029 0.000
End-stage renal disease -0.061 0.167 0.714 0.064 0.103 0.537
Osteroporosis -0.010 0.065 0.877 0.022 0.043 0.616
Baseline CCI=0 -0.037 0.052 0.475 -0.082 0.049 0.090
Baseline CCI=1-2 -0.163 0.063 0.009 -0.128 0.049 0.010
Baseline CCI=3-5 -0.295 0.113 0.009 -0.144 0.078 0.063
Baseline CCI=6-8 -0.468 0.188 0.013 -0.194 0.121 0.110
Baseline CCI more than 9 -0.635 0.279 0.023 -0.246 0.176 0.161
Baseline Beta blocker -0.246 0.033 0.000 -0.204 0.026 0.000
Baseline ACEI/ARB -0.089 0.034 0.008 -0.185 0.027 0.000
Baseline STATINS 1.211 0.035 0.000 1.896 0.027 0.000
Baseline STENT/PTCA 0.003 0.256 0.990 -0.323 0.302 0.285
Asthma 0.073 0.076 0.337 0.093 0.051 0.068
Baseline medication
Angiodedma&hyperkalemia -0.313 0.330 0.343 0.262 0.247 0.289
Hypotension 0.017 0.084 0.836 -0.048 0.050 0.338
Sinus bradycardia&heart block -0.065 0.048 0.176 0.009 0.032 0.783
Rhabdomyolysis 0.106 0.287 0.712 -0.362 0.164 0.027
Hyperkalemia 0.270 0.346 0.436 -0.106 0.254 0.678
Admission procedure/diagnosis
CABG -0.013 0.119 0.914
PTCA -0.143 0.517 0.782
Stent/PTCA -0.078 0.531 0.883
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CABG/stent/PTCA No CABG/stent/PTCA
Variables Estimator SE p-value Estimator SE p-value
Subendocardial infarction -0.155 0.032 0.000 -0.029 0.031 0.346
Congestive heart failure -0.103 0.037 0.006 -0.088 0.025 0.000
Cardiogenic shock 0.081 0.080 0.309 -0.012 0.113 0.914
Acute renal failure -0.006 0.053 0.910 0.055 0.034 0.107
Hypotension 0.046 0.064 0.477 0.037 0.054 0.493
Cardiac dysrhythmias -0.029 0.034 0.382 -0.087 0.026 0.001
Cardiac catheterization 0.007 0.046 0.883 0.035 0.091 0.703
Angiocardiography 0.044 0.043 0.307 0.259 0.091 0.004
Thromblytics and patelet inhibitors -0.164 0.161 0.307 0.088 0.184 0.633
Platelet inhibitors 0.035 0.055 0.525 0.425 0.092 0.000
Number of days in ICU=0
Number of days in ICU=1-3 -0.030 0.035 0.387 0.069 0.028 0.015
Number of days in ICU=4-10 -0.002 0.048 0.968 0.000 0.033 0.993
Number of days in ICU ¿10 -0.086 0.097 0.379 -0.003 0.088 0.976
Number of coronary care unit=0
Number of coronary care unit= 1-3 0.076 0.036 0.034 0.137 0.033 0.000
Number of coronary care unit= 4-10 0.080 0.049 0.100 0.105 0.038 0.006
Number of coronary care unit ¿10 -0.106 0.106 0.319 0.249 0.116 0.032
Total number of days in hospital
1 day in hospital 0.068 0.090 0.451 -0.197 0.068 0.004
2-5 days in hospital 0.044 0.060 0.459 0.045 0.039 0.245
6-10 days in hospital -0.080 0.056 0.155 -0.038 0.038 0.317
More than 10 days in hospital -0.090 0.087 0.299 -0.117 0.062 0.054
Acute respiratory failure/
Mechventilation in AMI admission -0.024 0.054 0.659 -0.076 0.040 0.056
Septic shock in AMI admission -0.081 0.290 0.781 -0.168 0.146 0.250
Physician visit during follow-up 0.245 0.041 0.000 0.096 0.029 0.001
Cardiologist visit during follow-up 0.034 0.034 0.321 0.147 0.028 0.000
Revascularization procudure
during follow-up -0.002 0.044 0.960 0.412 0.071 0.000
Number of hospital admission in baseline 0.028 0.041 0.491 -0.050 0.021 0.017
Number of days in hospital in baseline 0.002 0.003 0.507 0.001 0.001 0.595
Indicator for hospital admission in baseline 0.058 0.063 0.353 0.041 0.041 0.319
Number of admission to short-term
acute care hospital during follow up 0.005 0.047 0.913 -0.028 0.037 0.449
Number of days to short term acute
care hospital during follow up -0.024 0.007 0.001 -0.003 0.006 0.600
DOUGNUT -0.076 0.053 0.158 0.016 0.037 0.663
Low comorbidity level
Moderate comorbidity level -0.076 0.053 0.158 -0.072 0.040 0.071
HIgh comorbidity level -0.092 0.077 0.231 0.022 0.048 0.650
Current Beta blockers 1.128 0.036 0.000 0.896 0.027 0.000
Current ACEI/ARB 0.065 0.143 0.648 0.476 0.103 0.000
CurrentACEI 0.600 0.139 0.000 0.185 0.099 0.063
CurrentARB 0.482 0.134 0.000 0.004 0.096 0.964
Current comorbidity
Valvular disease or
Rheumatic heart disease -0.021 0.041 0.620 -0.008 0.028 0.765
Other neurological disorders -0.037 0.056 0.510 -0.015 0.034 0.654
Obesity -0.056 0.065 0.387 0.028 0.053 0.599
Coagulation deficiency 0.029 0.080 0.715 -0.048 0.048 0.315
Weight loss 0.010 0.073 0.895 -0.018 0.043 0.677
Fluid/electrolyte disorder 0.059 0.048 0.213 -0.096 0.031 0.002
Substance abuse -0.218 0.134 0.105 0.084 0.086 0.330
Blood loss&deficiency anemia -0.052 0.040 0.193 -0.094 0.027 0.001
Hypothyroidism -0.047 0.038 0.220 -0.038 0.028 0.175
Pulmonary Circ. Disorders -0.099 0.078 0.200 -0.020 0.045 0.659
Osteoarthritis -0.048 0.034 0.159 -0.014 0.026 0.598
GI bleed -0.021 0.071 0.768 -0.044 0.044 0.316
Use of screening 0.045 0.039 0.246 0.004 0.029 0.901
Use of wheelchair 0.108 0.097 0.268 0.044 0.048 0.353
Parkinson’s disease -0.069 0.137 0.618 -0.038 0.084 0.648
Use of rehabilitation -0.017 0.045 0.695 -0.004 0.033 0.898
Weakness 0.124 0.096 0.198 0.026 0.053 0.630
Vertigo -0.002 0.044 0.973 0.017 0.032 0.592
Fall/diﬃculty walking 0.003 0.052 0.954 0.056 0.033 0.091
Bladder dysfunction -0.035 0.053 0.512 0.037 0.037 0.326
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CABG/stent/PTCA No CABG/stent/PTCA
Variables Estimator SE p-value Estimator SE p-value
Decubitus -0.121 0.077 0.114 -0.005 0.046 0.913
Use of Oxygen -0.016 0.065 0.809 -0.021 0.039 0.581
Use of hospital bed 0.145 0.146 0.321 0.052 0.063 0.411
Use of ambulance 0.060 0.040 0.130 0.001 0.028 0.975
Nail care 0.067 0.052 0.197 0.131 0.032 0.683
Use of other assistive devices -0.156 0.092 0.091 0.029 0.053 0.588
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